WO2022009157A1

WO2022009157A1 - Lhc165 and spartalizumab combinations for treating solid tumors

Info

Publication number: WO2022009157A1
Application number: PCT/IB2021/056165
Authority: WO
Inventors: Tycho HEIMBACH; Jacqueline KINYAMU-AKUNDA; Chun Li; Nehal PARIKH
Original assignee: Novartis Ag
Priority date: 2020-07-10
Filing date: 2021-07-08
Publication date: 2022-01-13

Abstract

The present invention provides dosage regimens for intratumoral administration of 3-(5-amino-2-(4-(2-(3,3-difluoro-3-phosphonopropoxy)ethoxy)-2-methylphenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid (compound of Formula (I)) in combination with the administration of an anti-PD-1 antibody for treating solid tumors.

Description

LHC165 AND SPARTALIZUMAB COMBINATIONS FOR TREATING SOLID TUMORS

FIELD OF THE INVENTION

The present invention relates to 3-(5-amino-2-(4-(2-(3,3-difluoro-3- phosphonopropoxy)ethoxy)-2-methylphenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid and to pharmaceutical compositions comprising 3-(5-amino-2-(4-(2-(3,3-difluoro-3- phosphonopropoxy)ethoxy)-2-methylphenethyl)benzo[f][1 ,7]naphthyridin-8-yl)propanoic acid for use in treating solid tumors in combination with anti-PD-1 antibodies. The present invention relates to dosage regimens for intratumoral administration of 3-(5-amino-2-(4-(2-(3,3-difluoro-3- phosphonopropoxy)ethoxy)-2-methylphenethyl)benzo[f][1 ,7]naphthyridin-8-yl)propanoic acid in combination with the administration of an anti-PD-1 antibody for treating solid tumors.

BACKGROUND OF THE INVENTION

Toll-like receptors (TLRs) are pattern recognition receptors which play an essential role in the innate immunity, by recognizing invasion of microbial pathogens and initiating intracellular signal transduction pathways to trigger expression of genes, the products of which can control innate immune responses. Specifically, Toll like receptor (TLR) agonists activate innate immune cells through the TLR-MyD88-NFkβ and IRF3/7 pathways. TLR7, TLR8, and TLR9 belong to a subfamily of TLRs based on their genomic structure, sequence similarities, and homology. TLR7, TLR8, and TLR9 are located in intracellular endolysosomal compartments and show a unique pattern of cell type-specific expression that is thought to be responsible for different pathogen response profiles.

Small molecule agonists of TLR7 and/or TLR8 have been reported and shown to activate innate immune responses by inducing selected cytokine biosynthesis, the induction of co stimulatory molecules, and by increased antigen-presenting capacity. Such compounds include imidazoquinoline amine derivatives (U.S. Patent No. 4689338), imidazopyridine amine derivative (U.S. Patent No. 5446153), imidazonaphthyridine derivative (U.S. Patent No. 6194425), oxazoloquinoline amine derivatives (U.S. Patent No. 6110929); thiazoloquinoline amine derivatives (U.S. Patent No. 6110929), selenazoloquinoline amine derivatives (U.S. Patent No. 6110929), pyrazolopyridine derivatives (U.S. Patent No. 9145410), and benzonaphthyridine amine derivatives (U.S. Patent Nos. 8466167 and 9045470).

The synthetic TLR7 agonist, Imiquimod (1-(2-methylpropyl)-1H-imidazo[ 4,5-c]quinolin-4- amine) is FDA-approved in a cream formulation for the topical treatment of cutaneous basal cell carcinoma, actinic keratosis and genital warts, and has limited activity against cutaneous melanoma and breast tumors (J. Immunol. 2014, 193(9): 4722-4731). Systemic administration of Imiquimod, and structurally similar Resiquimod, is limited by cytokine-mediated adverse effects including severe flu-like symptoms (Expert Opin. Emerging Drugs (2010), 15:544-555). Consequently, Imiquimod is used exclusively in topical applications and is not used to treat deep, non-cutaneous tumors such as melanoma or solid tumors. An injectable lipid modified imidazoquinoline (TLR7/8 dual agonist) that forms a tissue depot with gradual, sustained release which allows for local TLR triggering activity without systemic cytokine release has been reported (J. Immunol.2014, 193(9): 4722–4731). However, this compound was shown to be ineffective for large tumors and in addition the serum concentration of this compound 24 hours post subcutaneous administration decreased by approximately 50% (Journal for ImmunoTherapy of Cancer, 2014, 2:12). Therefore, there remains a need for intratumoral administration of a TLR7 agonist with prolonged sustained release, which may benefit the treatment of large tumors. SUMMARY OF THE INVENTION There remains a need for new treatments and therapies for solid tumors, in particular melanoma, head and neck squamous cell carcinoma (HNSCC) and visceral tumors. International patent application WO2018211453A1 discloses the use of benzonaphthyridine derivatives as TLR7 agonists and their use in combination with checkpoint inhibitors to treat solid tumors, however there is no disclosure regarding an efficacious dose. Accordingly, the invention provides dose and dosing regimens for 3-(5-amino-2-(4-(2-(3,3-difluoro-3- phosphonopropoxy)ethoxy)-2-methylphenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid, or for pharmaceutical compositions comprising 3-(5-amino-2-(4-(2-(3,3-difluoro-3- phosphonopropoxy)ethoxy)-2-methylphenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid, used either alone or in combination with the administration of an anti-PD-1 antibody for treating solid tumors. The present invention provides the following aspects listed in the following items: Item 1. A therapeutic regimen for treating a solid tumor, comprising intratumorally administering a compound of Formula (I)

once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg and administering an anti-PD-1 antibody at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Item 2. A therapeutic regimen for treating a solid tumor, wherein the therapeutic regimen has a six cycle period dosing schedule comprising: a) intratumorally administering a compound of Formula (I)

for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and b) intravenously administering an anti-PD-1 antibody for each of the six cycle periods; and wherein: each cycle period is 28 days; the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6, and the anti-PD-1 antibody is intravenously administered at a flat dose of 400 mg on Day 1 of Cycles 1, 2, 3, 4, 5 and 6. Item 3. A method for treating a solid tumor in a subject in need thereof, comprising intratumorally administering a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg, and administering an anti-PD-1 antibody at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Item 4. Use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is administered at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Item 5. A combination comprising a compound of Formula (I) and an anti-PD-1 antibody for the use in the treatment of a solid tumor, wherein the compound of Formula (I) is at a flat dose of about 100 µg to about 600 µg and the anti-PD-1 antibody is at a dose selected from the group consisting of i) about 300 mg; ii) about 400 mg; iii) about 240 mg; iv) about 480 mg; v) about 200 mg; and vi) about 10 mg/kg. Item 6. A therapeutic regimen for treating a solid tumor, comprising (a) intratumorally administering a pharmaceutical composition comprising a compound of Formula (I)

once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and (b) administering an anti-PD-1 antibody at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Item 7. A therapeutic regimen for treating a solid tumor, wherein the therapeutic regimen has a six cycle period dosing schedule comprising: a) intratumorally administering a pharmaceutical composition comprising a compound of Formula (I)

for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the pharmaceutical composition comprising the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and b) intravenously administering an anti-PD-1 antibody for each of the six cycle periods; and wherein: each cycle period is 28 days; the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6, and the anti-PD-1 antibody is intravenously administered at a flat dose of 400 mg on Day 1 of Cycles 1, 2, 3, 4, 5 and 6. Item 8. A method for treating a solid tumor in a subject in need thereof, comprising (a) intratumorally administering a pharmaceutical composition comprising a compound of Formula (I)

once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and (b) administering an anti-PD-1 antibody at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Item 9. Use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is administered at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Item 10. A combination comprising a pharmaceutical composition comprising a compound of Formula (I) and an anti-PD-1 antibody for the use in the treatment of a solid tumor, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is administered at a dose selected from the group consisting of i) about 300 mg; ii) about 400 mg; iii) about 240 mg; iv) about 480 mg; v) about 200 mg; and vi) about 10 mg/kg. Item 11. In any one of Items 1 to 10 the anti-PD-1 antibody is selected from the group consisting of spartalizumab, nivolumab, pembrolizumab, pidilizumab and AMP-224. Item 12. In any one of Items 1 to 11 the anti-PD-1 antibody is spartalizumab. Item 13. A therapeutic regimen for treating a solid tumor, comprising intratumorally administering a compound of Formula (I)

once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg. Item 14. A therapeutic regimen for treating a solid tumor, wherein the therapeutic regimen has a six cycle period dosing schedule comprising intratumorally administering a compound of Formula (I)

for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and wherein: each cycle period is 28 days, and the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6. Item 15. A method for treating a solid tumor in a subject in need thereof, comprising administering a compound of Formula (I),

wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg. Item 16. Use of a compound of Formula (I) for the treatment of a solid tumor, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg. Item 17. A compound of Formula (I) for use in the treatment of a solid tumor, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg. Item 18. A therapeutic regimen for treating a solid tumor, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I)

once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Item 19. A therapeutic regimen for treating a solid tumor, wherein the therapeutic regimen has a six cycle period dosing schedule comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I)

for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the pharmaceutical composition comprising the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and wherein: each cycle period is 28 days, and the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6. Item 20. A method for treating a solid tumor in a subject in need thereof, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I)

once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Item 21. Use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor, wherein the pharmaceutical composition is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Item 22. A pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor, wherein the pharmaceutical composition is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Item 23. In any one of Item 1 to 22 the solid tumor is a breast cancer tumor, a bladder cancer tumor, a head and neck cancer tumor, head and neck squamous cell carcinoma (HNSCC), a non-small cell lung cancer tumor, a small cell lung cancer tumor, a colorectal cancer tumor, a gastrointestinal stromal tumor, a gastroesophageal carcinoma, a renal cell cancer tumor, a prostate cancer tumor, a liver cancer tumor, a colon cancer tumor, a pancreatic cancer tumor, an ovarian cancer tumor, a lymphoma, a cutaneous T-cell lymphoma, a visceral tumor or melanoma. Item 24. In any one of Item 1 to 23 the solid tumor is a breast cancer tumor, head and neck squamous cell carcinoma (HNSCC), a visceral tumor or melanoma. Item 25. In any one of Item 1 to 24 wherein the solid tumor is head and neck squamous cell carcinoma (HNSCC), a visceral tumor or melanoma. Item 26. In any one of Item 1 to 25 the solid tumor is head and neck squamous cell carcinoma (HNSCC). Item 27. In any one of Item 1 to 25 the solid tumor is a visceral tumor. Item 28. In any one of Item 1 to 25 the solid tumor is melanoma. DETAILED DESCRIPTION OF THE INVENTION Definitions The term “solid tumor,” as used herein, refers to an abnormal mass of tissue that usually does not contain cysts or liquid areas. In general, the term refers to cancerous (malignant) tumors, although a solid tumor may be a non-cancerous (benign) tumor. Examples of solid tumors are sarcomas, carcinomas, and lymphomas, which include, but are not limited to, a breast cancer tumor, a bladder cancer tumor, a head and neck cancer tumor (e.g. head and neck squamous cell carcinoma (HNSCC)), a non-small cell lung cancer tumor, a small cell lung cancer tumor, a colorectal cancer tumor, a gastrointestinal stromal tumor, a gastroesophageal carcinoma, a renal cell cancer tumor, a prostate cancer tumor, a liver cancer tumor, a colon cancer tumor, a pancreatic cancer tumor, an ovarian cancer tumor, a lymphoma, a cutaneous T-cell lymphoma, a visceral tumor or melanoma. The terms “combination”, as used herein means a non-fixed combination of active ingredients, by way of example, a compound of Formula (I) and an anti-PD-1 antibody, which are separate entities and are administered sequentially to a subject, where such administration provides therapeutically effective levels of the active ingredients in the body of the patient. The terms “composition” or “pharmaceutical composition,” as used herein, refers to a mixture of a compound of Formula (I) with a suspension of aluminum hydroxide particles and at least one and optionally more than one other pharmaceutically acceptable chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. The terms "flat dose" or "fixed dose", as used herein, refer to a specific quantity of an active ingredient (i.e. a compound of Formula (I) regardless of a subject's body weight or body size. The term “patient” or "subject", as used herein, encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, humans, chimpanzees, apes, monkeys, cattle, horses, sheep, goats, swine; rabbits, dogs, cats, rats, mice, guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish and the like. Frequently the patient is a human. The term “a subject in need thereof”, refers to a patient which would benefit biologically, medically or in quality of life from treatment. The term " in a sufficient amount", as used herein, refers to a volume of a liquid pharmaceutical composition comprising the compound of Formula (I) required to provide a fixed dose of the compound of Formula (I). By way of example, for a pharmaceutical composition comprising 1 mg/mL of compound of Formula (I), a volume of 600 µL is required to provide a dose of 600 µg. By way of example, for a pharmaceutical composition comprising 1 mg/mL of compound of Formula (I), a volume of 400 µL is required to provide a dose of 400 µg. By way of example, for a pharmaceutical composition comprising 1 mg/mL of compound of Formula (I), a volume of 200 µL is required to provide a dose of 200 µg. By way of example, for a pharmaceutical composition comprising 1 mg/mL of compound of Formula (I), a volume of 100 µL is required to provide a dose of 100 µg. The term “therapeutically effective amount,” as used herein, refers to an amount which may increase the immune response, ameliorate at least one symptom or clinical sign of a tumor and/or decrease the number and/or size of metastases. Ameliorating at least one symptom or clinical sign of a tumor can include a decrease in the size of a tumor, stabilization in the size or growth of a tumor, a reduction in the rate of growth of a tumor, an increase in tumor necrosis, a change in the tumor structure such as disintegration, a change in a biochemical marker associated with decrease in tumor establishment, a decrease in tumor progression or a decrease in tumor survival. An increase in immune response refers to an increase in at least one cell-mediated immune response of a cell population that includes cells of a tumor and refers to an increase in at least one biochemical, histological, or immunological marker associated with improvement of the immunological profile of the tumor microenvironment. Markers in which an increase in the amount of the marker is associated with an improvement of the immunological profile of the tumor microenvironment include, but are not limited to, interferon-alpha; interferon-gamma; interferon inducible proteins; Interferon gamma-induced protein 10 (IP-10); TNF-alpha; chemokines such as CCL2, CCL3, CCL4, CXCL2; activated T- cells; activated B-cells; activated NK-cells; tumor specific T-cells, activated tumor associated macrophages; chemokine receptors such as CCR6; or tumor associated lymphoid aggregates. Markers associated with a tumor microenvironment can be determined, for example, by analysis of a biopsy (for example needle biopsy) from the tumor, the localized tumor region, or a tumor draining lymph node. Analysis for the markers can be done using standard techniques such as by histology (HNE stain), flow cytometry, gene expression assays (quantitative PCR), RNA sequencing, immunochemistry techniques, as well as other techniques commonly known to those of ordinary skill in the art. The term “TLR7 agonist”, as used herein, refers to a compound which targets or activates the biological activity of Toll-like Receptor 7 (TLR7). The term “treat”, “treating”, “treatment” or “therapy” as used herein comprises a treatment relieving, reducing or alleviating at least one symptom in a patient, or effecting a delay of progression of a disease in a patient. For example, treatment can be the diminishment of one or several symptoms of a disorder or complete eradication of a disorder, such as cancer. Within the meaning of the present invention, the term “treat” also denotes to arrest, delay the onset (i.e., the period prior to clinical manifestation of a disease) and/or reduce the risk of developing or worsening a disease. The term “therapeutic regimen”, as used herein, refers to the pattern of dosing used during the treatment of the disease or disorder and is also referred to as "dosing regimen" or "dosing schedule". The term “about”, “approximately”, or “approximate”, when used in connection with a numerical value, means that a collection or range of values is included. For example, “about X” includes a range of values that are ±20%, ±10%, ±5%, ±2%, ±1%, ±0.5%, ±0.2%, or ±0.1% of X, where X is a numerical value. In one embodiment, the term “about” refers to a range of values which are 10% more or less than the specified value. In another embodiment, the term “about” refers to a range of values which are 5% more or less than the specified value. In another embodiment, the term “about” refers to a range of values which are 1% more or less than the specified value. Recitation of ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. A range used herein, unless otherwise specified, includes the two limits of the range. For example, the terms “between X and Y” and “range from X to Y, are inclusive of X and Y and the integers there between. On the other hand, when a series of individual values are referred to in the disclosure, any range including any of the two individual values as the two end points is also conceived in this disclosure. For example, the expression "a dose of about 10 mg, about 20 mg, about 40 mg, about 80 mg, about 120 mg, about 160 mg, about 240 mg, about 300 mg, about 500 mg or about 800 mg", also means “a dose ranging from 10 to 800 mg”. The compound names provided herein were obtained using ChemBioDraw Ultra 14.0 (CambridgeSoft®). As used herein, the term "a,” "an,” "the” and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context. Description of Embodiments of the Invention The invention provides dosage and dosing regimens for the administration of 3-(5-amino-2- (4-(2-(3,3-difluoro-3-phosphonopropoxy)ethoxy)-2-methylphenethyl)benzo[f][1,7]naphthyridin-8- yl)propanoic acid (compound of Formula (I),

either alone as a single agent, or in combination with an anti-PD-1 antibody, for the treatment of solid tumors. The invention further provides dosage and dosing regimens for the administration of pharmaceutical compositions comprising a compound of Formula (I), either alone, or in combination with an anti-PD-1 antibody, for the treatment of solid tumors. Dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I), either alone as a single agent, or in combination with an anti-PD-1 antibody, can be the administration of compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks during a cycle period, with such administration occurring for 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 cycle periods. A cycle period is the number and timing, or recommended repetitions, of therapy and are usually expressed as the number of days. Examples of a cycle period can be every 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. A dosing schedule can include a dose delay (drug holiday), wherein the compound of Formula (I) is not administered during one or more cycle periods. Such dose delays correspond to a cycle period and can be for 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days to 31 days. Accordingly, for a dosing schedule (therapeutic regimen) which includes a dose delay, compound of Formula (I) is first administered intratumorally during one or more cycle periods, then compound of Formula (I) is not administered during one or more subsequent cycle periods (dose delay), and then compound of Formula (I) is again administered intratumorally during one or more additional cycle periods. Alternatively, for a dosing schedule which includes a dose delay, compound of Formula (I) is first administered intratumorally during one or more cycle periods, then compound of Formula (I) is not administered during one or more subsequent cycle periods (dose delay). By way of example, during a nine cycle period dosing schedule with dose delay, compound of Formula (I) is administered intratumorally during cycles 1, 3, 5, 7 and 9, with a dose delay during cycles 2, 4, 6, and 8 wherein compound of Formula (I) is not administered. In this example, the dosing schedule comprises nine cycle periods in which the compound of Formula (I) is administered intratumorally for five cycle periods with four dose delays, wherein each dose delay is for one cycle period occurring between each cycle period in which compound of Formula (I) is administered. Alternatively, during an eight cycle period dosing schedule with dose delay, compound of Formula (I) is administered intratumorally during cycles 1, 2, 4, 5, 7 and 8, with a dose delay during cycles 3 and 6 wherein compound of Formula (I) is not administered. In this example, the dosing schedule comprises eight cycle periods in which the compound of Formula (I) is administered intratumorally for six cycle periods with two dose delays, wherein each dose delay is for one cycle period and the compound of Formula (I) is administered intratumorally for two consecutive cycle periods before each dose delay. In addition, during a six cycle period dosing schedule with dose delay, compound of Formula (I) is administered intratumorally during cycles 1, 2, 5 and 6, with a dose delay during cycles 3 and 4 wherein compound of Formula (I) is not administered. In this example, the dosing schedule comprises six cycle periods in which the compound of Formula (I) is administered intratumorally for four cycle periods with a dose delay for two consecutive cycle periods, wherein the compound of Formula (I) is administered intratumorally for two consecutive cycle periods before the dose delay of two cycle periods. Compound of Formula (I) is administered during such dosing schedules and cycle periods described above at a flat dose of about 100 µg to about 600 µg. Certain aspects and examples of dosage and dosing regimens (therapeutic regimens) for the compound of Formula (I) are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the such dosage and dosage regimens used to treat solid tumors. Embodiment 1. A therapeutic regimen for treating a solid tumor, comprising intratumorally administering a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 2. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 200 µg to about 600 µg. Embodiment 3. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 4. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 400 µg. Embodiment 5. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 600 µg. Embodiment 6. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 100 µg to about 600 µg. Embodiment 7. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 200 µg to about 600 µg. Embodiment 8. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 400 µg to about 600 µg. Embodiment 9. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 400 µg. Embodiment 10. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 600 µg. Embodiment 11. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 12. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 200 µg to about 600 µg. Embodiment 13. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 14. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 400 µg. Embodiment 15. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 600 µg. Embodiment 16. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 17. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 200 µg to about 600 µg. Embodiment 18. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 19. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 400 µg. Embodiment 20. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 600 µg. Embodiment 21. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 22. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 200 µg to about 600 µg. Embodiment 23. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 24. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 400 µg. Embodiment 25. The therapeutic regimen for treating a solid tumor of Embodiment 1, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 600 µg. Embodiment 26. The therapeutic regimen for treating a solid tumor of any one of Embodiments 1 to 25, wherein the compound of Formula (I) is intratumorally administered for one or more cycle periods. Embodiment 27. The therapeutic regimen for treating a solid tumor of any one of Embodiments 1 to 26, wherein the compound of Formula (I) is intratumorally administered for two or more cycle periods. Embodiment 28. The therapeutic regimen for treating a solid tumor of any one of Embodiments 1 to 27, further comprising a dose delay for one or more cycle periods. Embodiment 29. The therapeutic regimen for treating a solid tumor of any one of Embodiments 1 to 27, further comprising one or more dose delays, wherein each dose delay is for one cycle period. Embodiment 30. The therapeutic regimen for treating a solid tumor of any one of Embodiments 1 to 27, further comprising one or more dose delays, wherein each dose delay is for two or more consecutive cycle periods. Embodiment 31. The therapeutic regimen for treating a solid tumor of any one of Embodiments 1 to 27, further comprising one or more dose delays, wherein each dose delay is for two consecutive cycle periods. Embodiment 32. The therapeutic regimen for treating a solid tumor of any one of Embodiments 1 to 27, further comprising a dose delay, wherein the dose delay is for two consecutive cycle periods and the compound of Formula (I) is intratumorally administered for two consecutive cycle periods before the dose delay. Embodiment 33. The therapeutic regimen for treating a solid tumor of any one of Embodiments 1 to 27, further comprising a dose delay, wherein the dose delay is for two consecutive cycle periods, and wherein the compound of Formula (I) is intratumorally administered for two consecutive cycle periods before the dose delay, and the compound of Formula (I) is intratumorally administered for two consecutive cycle periods after the dose Embodiment 34. The therapeutic regimen for treating a solid tumor of any one of Embodiments 26 to 33, wherein each cycle period is 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 35. The therapeutic regimen for treating a solid tumor of any one of Embodiments 26 to 34, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 36. The therapeutic regimen for treating a solid tumor of any one of Embodiments 26 to 35, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days or 28 days. Embodiment 37. The therapeutic regimen for treating a solid tumor of any one of Embodiments 26 to 37, wherein each cycle period is 28 days. Embodiment 38. A therapeutic regimen for treating a solid tumor, wherein the therapeutic regimen has a six cycle period dosing schedule comprising intratumorally administering a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and wherein: each cycle period is 28 days, and the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6. Embodiment 39. The therapeutic regimen for treating a solid tumor of Embodiment 38, wherein the therapeutic regimen has a six cycle period dosing schedule comprising intratumorally administering a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and wherein: each cycle period is 28 days, and the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6. Embodiment 40. The therapeutic regimen for treating a solid tumor of Embodiment 38, wherein the therapeutic regimen has a six cycle period dosing schedule comprising intratumorally administering a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and wherein: each cycle period is 28 days, and the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6. Embodiment 41. The therapeutic regimen for treating a solid tumor of Embodiment 38, wherein the therapeutic regimen has a six cycle period dosing schedule comprising intratumorally administering a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and wherein: each cycle period is 28 days, and the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6. Embodiment 42. The therapeutic regimen for treating a solid tumor of Embodiment 38, wherein the therapeutic regimen has a six cycle period dosing schedule comprising intratumorally administering a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and wherein: each cycle period is 28 days, and the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6. The invention further provides a method of treating a solid tumor in a subject in need thereof using such dosage and dosage regimens, wherein the method comprises intratumorally administering a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg. Certain aspects and examples of such methods using a compound of Formula (I) are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of such methods to treat solid tumors. Embodiment 43. A method for treating a solid tumor in a subject in need thereof, comprising administering a compound of Formula (I), wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 44. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 200 µg to about 600 µg. Embodiment 45. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 46. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 400 µg. Embodiment 47. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 600 µg. Embodiment 48. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 100 µg to about 600 µg. Embodiment 49. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 200 µg to about 600 µg. Embodiment 50. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 400 µg to about 600 µg. Embodiment 51. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 400 µg. Embodiment 52. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 600 µg. Embodiment 53. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 54. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 200 µg to about 600 µg. Embodiment 55. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 56. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 400 µg. Embodiment 57. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 600 µg. Embodiment 58. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 59. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 200 µg to about 600 µg. Embodiment 60. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 61. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 400 µg. Embodiment 62. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 600 µg. Embodiment 63. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 64. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 200 µg to about 600 µg. Embodiment 65. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 66. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 400 µg. Embodiment 67. The method for treating a solid tumor of Embodiment 43, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 600 µg. Embodiment 68. The method of for treating a solid tumor any one of Embodiments 43 to 67, wherein the compound of Formula (I) is administered in a therapeutically effective amount. Embodiment 69. The method for treating a solid tumor of any one of Embodiments 43 to 68, wherein the compound of Formula (I) is intratumorally administered for one or more cycle periods. Embodiment 70. The method for treating a solid tumor of any one of Embodiments 43 to 68, wherein the compound of Formula (I) is intratumorally administered for two or more cycle periods. Embodiment 71. The method for treating a solid tumor of any one of Embodiments 43 to 70, further comprising a dose delay for one or more cycle periods. Embodiment 72. The method for treating a solid tumor of any one of Embodiments 43 to 70, further comprising one or more dose delays, wherein each dose delay is for one cycle period. Embodiment 73. The method for treating a solid tumor of any one of Embodiments 43 to 70, further comprising one or more dose delays, wherein each dose delay is for two or more consecutive cycle periods. Embodiment 74. The method for treating a solid tumor of any one of Embodiments 43 to 70, further comprising one or more dose delays, wherein each dose delay is for two consecutive cycle periods. Embodiment 75. The method for treating a solid tumor of any one of Embodiments 43 to 70, further comprising a dose delay, wherein the dose delay is for two consecutive cycle periods and the compound of Formula (I) is administered for two consecutive cycle periods before the dose delay. Embodiment 76. The method for treating a solid tumor of any one of Embodiments 43 to 70, further comprising a dose delay, wherein the dose delay is for two consecutive cycle periods, and wherein the compound of Formula (I) is intratumorally administered for two consecutive cycle periods before the dose delay, and the compound of Formula (I) is intratumorally administered for two consecutive cycle periods after the dose delay Embodiment 77. The method for treating a solid tumor of any one of Embodiments 69 to 76, wherein each cycle period is 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 78. The method for treating a solid tumor of any one of Embodiments 69 to 77, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 79. The method for treating a solid tumor of any one of Embodiments 69 to 78, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days or 28 days. Embodiment 80. The method for treating a solid tumor of any one of Embodiments 69 to 79, wherein each cycle period is 28 days. The invention further provides the use of a compound of Formula (I) for the treatment of a solid tumor, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg. Certain aspects and examples of such uses of a compound of Formula (I) are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of such uses to treat solid tumors. Embodiment 81. Use of a compound of Formula (I) for the treatment of a solid tumor, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 82. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is intratumorally administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeksat a flat dose of about 200 µg to about 600 µg. Embodiment 83. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 84. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 400 µg. Embodiment 85. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 600 µg. Embodiment 86. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 100 µg to about 600 µg. Embodiment 87. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 200 µg to about 600 µg. Embodiment 88. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 400 µg to about 600 µg. Embodiment 89. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 400 µg. Embodiment 90. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 600 µg. Embodiment 91. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 92. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 200 µg to about 600 µg. Embodiment 93. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 94. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 400 µg. Embodiment 95. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 600 µg. Embodiment 96. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 97. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 200 µg to about 600 µg. Embodiment 98. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 99. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 400 µg. Embodiment 100. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 600 µg. Embodiment 101. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 102. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 200 µg to about 600 µg. Embodiment 103. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 104. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 400 µg once. Embodiment 105. The use of a compound of Formula (I) for the treatment of a solid tumor of Embodiment 81, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 600 µg. The invention further provides a compound of Formula (I) for the use in the treatment of a solid tumor, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg. Certain aspects and examples of such uses of a compound of Formula (I) are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of such uses to treat solid tumors. Embodiment 106. A compound of Formula (I) for use in the treatment of a solid tumor, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 107. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 200 µg to about 600 µg. Embodiment 108. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 109. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 400 µg. Embodiment 110. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 600 µg. Embodiment 111. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 100 µg to about 600 µg. Embodiment 112. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 200 µg to about 600 µg. Embodiment 113. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 400 µg to about 600 µg. Embodiment 114. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 400 µg. Embodiment 115. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 600 µg. Embodiment 116. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 117. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 200 µg to about 600 µg. Embodiment 118. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 119. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 400 µg. Embodiment 120. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 600 µg. Embodiment 121. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every three weeksat a flat dose of about 100 µg to about 600 µg. Embodiment 122. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every three weeksat a flat dose of about 200 µg to about 600 µg. Embodiment 123. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 124. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 400 µg. Embodiment 125. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 600 µg. Embodiment 126. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 100 µg to about 600 µg. Embodiment 127. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 200 µg to about 600 µg. Embodiment 128. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 400 µg to about 600 µg. Embodiment 129. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 400 µg. Embodiment 130. The compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 106, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 600 µg. The invention also provides dosage and dosing regimens for pharmaceutical composition comprising a compound of Formula (I), for the treatment of solid tumors. Certain aspects and examples of dosage and dosing regimens (therapeutic regimen) for pharmaceutical compositions comprising a compound of Formula (I) are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of such dosage and dosage regimens used to treat solid tumors. Embodiment 131. A therapeutic regimen for treating a solid tumor, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 132. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 133. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 134. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 135. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 136. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 137. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 138. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 139. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 140. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 141. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 142. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 143. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 144. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 145. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 146. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 147. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 148. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 149. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 150. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 151. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 152. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 153. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 154. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 155. The therapeutic regimen for treating a solid tumor of Embodiment 131, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 156. The therapeutic regimen for treating a solid tumor of any one of Embodiments 131 to 155, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for one or more cycle periods. Embodiment 157. The therapeutic regimen for treating a solid tumor of any one of Embodiments 131 to 155, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for two or more cycle periods. Embodiment 158. The therapeutic regimen for treating a solid tumor of any one of Embodiments 131 to 157, further comprising a dose delay for one or more cycle periods. Embodiment 159. The therapeutic regimen for treating a solid tumor of any one of Embodiments 131 to 157, further comprising one or more dose delays, wherein each dose delay is for one cycle period. Embodiment 160. The therapeutic regimen for treating a solid tumor of any one of Embodiments 131 to 157, further comprising one or more dose delays, wherein each dose delay is for two or more consecutive cycle periods. Embodiment 161. The therapeutic regimen of for treating a solid tumor any one of Embodiments 131 to 157, further comprising one or more dose delays, wherein each dose delay is for two consecutive cycle periods. Embodiment 162. The therapeutic regimen for treating a solid tumor of any one of Embodiments 131 to 157, further comprising a dose delay, wherein the dose delay is for two consecutive cycle periods and the pharmaceutical composition comprising the compound of Formula (I) is administered for two consecutive cycle periods before the dose delay. Embodiment 163. The therapeutic regimen for treating a solid tumor of any one of Embodiments 131 to 157, further comprising a dose delay, wherein the dose delay is for two consecutive cycle periods, and wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for two consecutive cycle periods before the dose delay, and the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for two consecutive cycle periods after the dose delay Embodiment 164. The therapeutic regimen for treating a solid tumor of any one of Embodiments 156 to 163, wherein each cycle period is 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 165. The therapeutic regimen for treating a solid tumor of any one of Embodiments 156 to 164, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 166. The therapeutic regimen for treating a solid tumor of any one of Embodiments 156 to 165, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days or 28 days. Embodiment 167. The therapeutic regimen for treating a solid tumor of any one of Embodiments 156 to 166, wherein each cycle period is 28 days. Embodiment 168. A therapeutic regimen for treating a solid tumor, wherein the therapeutic regimen has a six cycle period dosing schedule comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the pharmaceutical composition comprising the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and wherein: each cycle period is 28 days, and the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6. Embodiment 169. The therapeutic regimen for treating a solid tumor of Embodiment 168, wherein the therapeutic regimen has a six cycle period dosing schedule comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the pharmaceutical composition comprising the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and wherein: each cycle period is 28 days, and the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6. Embodiment 170. The therapeutic regimen for treating a solid tumor of Embodiment 168, wherein the therapeutic regimen has a six cycle period dosing schedule comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the pharmaceutical composition comprising the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and wherein: each cycle period is 28 days, and the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6. Embodiment 171. The therapeutic regimen for treating a solid tumor of Embodiment 168, wherein the therapeutic regimen has a six cycle period dosing schedule comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the pharmaceutical composition comprising the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and wherein: each cycle period is 28 days, and the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6. Embodiment 172. The therapeutic regimen for treating a solid tumor of Embodiment 168, wherein the therapeutic regimen has a six cycle period dosing schedule comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the pharmaceutical composition comprising the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and wherein: each cycle period is 28 days, and the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6. The invention further provides a method of treating a solid tumor in a subject in need thereof using such dosage and dosage regimens, wherein the method comprises intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a dose of about 100 µg to about 600 µg. Certain aspects and examples of such methods using a pharmaceutical composition comprising a compound of Formula (I) are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of methods used to treat solid tumors. Embodiment 173. A method for treating a solid tumor in a subject in need thereof, comprising intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 174. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 175. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 176. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 177. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 178. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 179. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 180. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 181. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 182. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 183. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 184. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 185. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 186. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 187. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 188. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 189. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 190. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 191. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 192. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 193. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 194. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 195. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 196. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 197. The method for treating a solid tumor of Embodiment 173, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 198. The method for treating a solid tumor of any one of Embodiments 173 to 197, wherein the pharmaceutical composition comprises a therapeutically effective amount of the compound of Formula (I). Embodiment 199. The method for treating a solid tumor of any one of Embodiments 173 to 198, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for one or more cycle periods. Embodiment 200. The method for treating a solid tumor of any one of Embodiments 173 to 198, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for two or more cycle periods. Embodiment 201. The method for treating a solid tumor of any one of Embodiments 173 to 200, further comprising a dose delay for one or more cycle periods. Embodiment 202. The method for treating a solid tumor of any one of Embodiments 173 to 200, further comprising one or more dose delays, wherein each dose delay is for one cycle period. Embodiment 203. The method for treating a solid tumor of any one of Embodiments 173 to 200, further comprising one or more dose delays, wherein each dose delay is for two or more consecutive cycle periods. Embodiment 204. The method for treating a solid tumor of any one of Embodiments 173 to 200, further comprising one or more dose delays, wherein each dose delay is for two consecutive cycle periods. Embodiment 205. The method for treating a solid tumor of any one of Embodiments 173 to 200, further comprising a dose delay, wherein the dose delay is for two consecutive cycle periods and the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for two consecutive cycle periods before the dose delay. Embodiment 206. The method for treating a solid tumor of any one of Embodiments 173 to 200, further comprising a dose delay, wherein the dose delay is for two consecutive cycle periods, and wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for two consecutive cycle periods before the dose delay, and the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for two consecutive cycle periods after the dose delay Embodiment 207. The method for treating a solid tumor of any one of Embodiments 199 to 206, wherein each cycle period is 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 208. The method for treating a solid tumor of any one of Embodiments 199 to 207, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 209. The method for treating a solid tumor of any one of Embodiments 199 to 208, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days or 28 days. Embodiment 210. The method for treating a solid tumor of any one of Embodiments 199 to 209, wherein each cycle period is 28 days. The invention further provides the use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor, wherein the pharmaceutical composition is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Certain aspects and examples of such uses of a compound of Formula (I) are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of such uses to treat solid tumors. Embodiment 211. Use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor, wherein the pharmaceutical composition is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 212. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 213. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 214. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 215. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 216. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 217. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 218. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 219. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 220. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 221. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 222. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 223. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 224. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 225. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 226. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 227. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 228. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 229. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 230. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 231. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 232. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 233. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 234. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 235. The use of a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a solid tumor of Embodiment 211, wherein the pharmaceutical composition is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. The invention further provides a pharmaceutical composition comprising a compound of Formula (I) for the use in the treatment of a solid tumor, wherein the pharmaceutical composition is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Certain aspects and examples of such uses of a pharmaceutical composition comprising a compound of Formula (I) are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of such uses to treat solid tumors. Embodiment 236. A pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor, wherein the pharmaceutical composition is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 237. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 238. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 239. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 240. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 241. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 242. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 243. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 244. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 245. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 246. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 247. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 248. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 249. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 250. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 251. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 252. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 253. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 254. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 255. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 256. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg. Embodiment 257. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 258. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 259. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 260. The pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of a solid tumor of Embodiment 236, wherein the pharmaceutical composition is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 261. In any one of Embodiments 1 to 260, wherein the solid tumor is a breast cancer tumor, a bladder cancer tumor, a head and neck cancer tumor, head and neck squamous cell carcinoma (HNSCC), a non-small cell lung cancer tumor, a small cell lung cancer tumor, a colorectal cancer tumor, a gastrointestinal stromal tumor, a gastroesophageal carcinoma, a renal cell cancer tumor, a prostate cancer tumor, a liver cancer tumor, a colon cancer tumor, a pancreatic cancer tumor, an ovarian cancer tumor, a lymphoma, a cutaneous T-cell lymphoma, a visceral tumor or melanoma. Embodiment 262. In any one of Embodiments 1 to 261, wherein the solid tumor is a breast cancer tumor, head and neck squamous cell carcinoma (HNSCC), a visceral tumor or melanoma. Embodiment 263. In any one of Embodiments 1 to 262, wherein the solid tumor is head and neck squamous cell carcinoma (HNSCC), a visceral tumor or melanoma. Embodiment 264. In any one of Embodiments 1 to 263, wherein the solid tumor is head and neck squamous cell carcinoma (HNSCC). Embodiment 265. In any one of Embodiments 1 to 263, wherein the solid tumor is a visceral tumor. Embodiment 266. In any one of Embodiments 1 to 263, wherein the solid tumor is melanoma. Combination Therapy with anti-PD-1 antibodies PD-1 is a CD28/CTLA-4 family member expressed, e.g., on activated CD4⁺ and CD8⁺ T cells, T_regs, and B cells. It negatively regulates effector T cell signaling and function. PD-1 is induced on tumor-infiltrating T cells, and can result in functional exhaustion or dysfunction (Keir et al. (2008) Annu. Rev. Immunol.26:677-704; Pardoll et al. (2012) Nat Rev Cancer 12(4):252- 64). PD-1 delivers a coinhibitory signal upon binding to either of its two ligands, Programmed Death- Ligand 1 (PD-L1) or Programed Death- Ligand 2 (PD-L2). PD-L1 is expressed on a number of cell types, including T cells, Natural killer (NK) cells, macrophages, dendritic cells (DCs), B cells, epithelial cells, vascular endothelial cells, as well as many types of tumors. High expression of PD-L1 on murine and human tumors has been linked to poor clinical outcomes in a variety of cancers (Keir et al. (2008) Annu. Rev. Immunol.26:677-704; Pardoll et al. (2012) Nat Rev Cancer 12(4):252-64). PD-L2 is expressed on dendritic cells, macrophages, and some tumors. Blockade of the PD-1 pathway has been pre-clinically and clinically validate for cancer immunotherapy. Both preclinical and clinical studies have demonstrated that anti-PD-1 blockade can restore activity of effector T cells and results in robust anti-tumor response. For example, blockade of PD-1 pathway can restore exhausted/dysfunctional effector T cell function (e.g. proliferation, IFN-g secretion, or cytolytic function) and/or inhibit T_reg cell function (Keir et al. (2008) Annu. Rev. Immunol.26:677-704; Pardoll et al. (2012) Nat Rev Cancer 12(4):252- 64). Blockade of the PD-1 pathway can be effected with an antibody, an antigen binding fragment thereof, an immunoadhesin, a fusion protein, or oligopeptide of PD-1, PD-L1 and/or PD-L2. The invention also provides dosage and dosing regimens for the intratumoral administration of a compound of Formula (I) in combination with administration of an anti-PD-1 antibody for the treatment of solid tumors. In one embodiment, the anti-PD-1 antibodies used in combination with a compound of Formula (I) includes PDR001 (spartalizumab; see ncit.nci.nih.gov/ncitbrowser code C121625; UNII number QOG25L6Z8Z; CAS number 1935694-88-4), MDX-1106 (nivolumab; see ncit.nci.nih.gov/ncitbrowser code C68814; UNII number 31YO63LBSN; CAS number 946414- 94-4), MK3475 (pembrolizumab; see ncit.nci.nih.gov/ncitbrowser code C106432; UNII number DPT0O3T46P; CAS number 1374853-91-4), CT-011 (pidilizumab; see ncit.nci.nih.gov/ncitbrowser code C71014; UNII number B932PAQ1BQ; CAS number 1036730- 42-3), AMP-224 (see ncit.nci.nih.gov/ncitbrowser code C97039), or an anti-PD-1 antibody as described in W02015112900 published on July 30, 2015, entitled “Antibody Molecules to PD-1 and Uses Thereof,” which is herein incorporated by reference in its entirety. In a preferred embodiment, the anti-PD-1 antibody used in combination with a compound of Formula (I) is spartalizumab (PDR001). In one embodiment, the anti-PD-1 antibody comprises at least one, two, three, four, five or six complementarity determining regions (CDRs) (or collectively all of the CDRs) from a heavy and light chain variable region comprising an amino acid sequence shown in Table 1 (e.g., from the heavy and light chain variable region sequences of BAP049-Clone-E or BAP049-Clone-B disclosed in Table 1), or encoded by a nucleotide sequence shown in Table 1. In some embodiments, the CDRs are according to the Kabat definition (e.g., as set out in Table 1). In some embodiments, the CDRs are according to the Chothia definition (e.g., as set out in Table 1). In some embodiments, the CDRs are according to the combined CDR definitions of both Kabat and Chothia (e.g., as set out in Table 1). In one embodiment, the combination of Kabat and Chothia CDR of VHCDR1 comprises the amino acid sequence GYTFTTYWMH (SEQ ID NO: 1). In one embodiment, one or more of the CDRs (or collectively all of the CDRs) have one, two, three, four, five, six or more changes, e.g., amino acid substitutions (e.g., conservative amino acid substitutions) or deletions, relative to an amino acid sequence shown in Table 1, or encoded by a nucleotide sequence shown in Table 1. In one embodiment, the anti-PD-1 antibody comprises a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 2, a VHCDR2 amino acid sequence of SEQ ID NO: 3, and a VHCDR3 amino acid sequence of SEQ ID NO: 4; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 11, a VLCDR2 amino acid sequence of SEQ ID NO: 12, and a VLCDR3 amino acid sequence of SEQ ID NO: 13, each disclosed in Table 1. In one embodiment, the antibody molecule comprises a VH comprising a VHCDR1 encoded by the nucleotide sequence of SEQ ID NO: 25, a VHCDR2 encoded by the nucleotide sequence of SEQ ID NO: 26, and a VHCDR3 encoded by the nucleotide sequence of SEQ ID NO: 27; and a VL comprising a VLCDR1 encoded by the nucleotide sequence of SEQ ID NO: 30, a VLCDR2 encoded by the nucleotide sequence of SEQ ID NO: 31, and a VLCDR3 encoded by the nucleotide sequence of SEQ ID NO: 32, each disclosed in Table 1. In one embodiment, the anti-PD-1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 7, or an amino acid sequence at least 85%, 90%, 95%, or 99% identical or higher to SEQ ID NO: 7. In one embodiment, the anti-PD-1 antibody comprises a VL comprising the amino acid sequence of SEQ ID NO: 21, or an amino acid sequence at least 85%, 90%, 95%, or 99% identical or higher to SEQ ID NO: 21. In one embodiment, the anti-PD- 1 antibody comprises a VL comprising the amino acid sequence of SEQ ID NO:17, or an amino acid sequence at least 85%, 90%, 95%, or 99% identical or higher to SEQ ID NO: 17. In one embodiment, the anti-PD-1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 21. In one embodiment, the anti-PD-1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 17. In one embodiment, the antibody molecule comprises a VH encoded by the nucleotide sequence of SEQ ID NO: 8, or a nucleotide sequence at least 85%, 90%, 95%, or 99% identical or higher to SEQ ID NO: 8. In one embodiment, the antibody molecule comprises a VL encoded by the nucleotide sequence of SEQ ID NO: 22 or 18, or a nucleotide sequence at least 85%, 90%, 95%, or 99% identical or higher to SEQ ID NO: 22 or 18. In one embodiment, the antibody molecule comprises a VH encoded by the nucleotide sequence of SEQ ID NO: 8 and a VL encoded by the nucleotide sequence of SEQ ID NO: 22 or 18. In one embodiment, the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9, or an amino acid sequence at least 85%, 90%, 95%, or 99% identical or higher to SEQ ID NO: 9. In one embodiment, the anti-PD-1 antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 23, or an amino acid sequence at least 85%, 90%, 95%, or 99% identical or higher to SEQ ID NO: 23. In one embodiment, the anti-PD-1 antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 19, or an amino acid sequence at least 85%, 90%, 95%, or 99% identical or higher to SEQ ID NO: 19. In one embodiment, the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 23. In one embodiment, the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 19. In one embodiment, the antibody molecule comprises a heavy chain encoded by the nucleotide sequence of SEQ ID NO: 10, or a nucleotide sequence at least 85%, 90%, 95%, or 99% identical or higher to SEQ ID NO: 10. In one embodiment, the antibody molecule comprises a light chain encoded by the nucleotide sequence of SEQ ID NO: 24 or 20, or a nucleotide sequence at least 85%, 90%, 95%, or 99% identical or higher to SEQ ID NO: 24 or 20. In one embodiment, the antibody molecule comprises a heavy chain encoded by the nucleotide sequence of SEQ ID NO: 10 and a light chain encoded by the nucleotide sequence of SEQ ID NO: 24 or 20. The antibody molecules described herein can be made by vectors, host cells, and methods described in W02015112900, incorporated by reference in its entirety. The VH and VL regions can be subdivided into regions of hypervariability, termed "complementarity determining regions" (CDR), interspersed with regions that are more conserved, termed "framework regions" (FR or FW). The extent of the framework region and CDRs has been precisely defined by a number of methods (see, Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No.91-3242; Chothia, C. et al. (1987) J. Mol. Biol.196:901-917; and the AbM definition used by Oxford Molecular's AbM antibody modeling software. See, generally, e.g., Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual (Ed.: Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg). The terms “complementarity determining region,” and “CDR,” as used herein refer to the sequences of amino acids within antibody variable regions which confer antigen specificity and binding affinity. In general, there are three CDRs in each heavy chain variable region (HCDR1, HCDR2, HCDR3) and three CDRs in each light chain variable region (LCDR1, LCDR2, LCDR3). The precise amino acid sequence boundaries of a given CDR can be determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 (“Chothia” numbering scheme). As used herein, the CDRs defined according the “Chothia” number scheme are also sometimes referred to as “hypervariable loops.” For example, under Kabat, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3); and the CDR amino acid residues in the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3). Under Chothia the CDR amino acids in the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3); and the amino acid residues in VL are numbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3). By combining the CDR definitions of both Kabat and Chothia, the CDRs consist of amino acid residues 26-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3) in human VH and amino acid residues 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3) in human VL. Generally, unless specifically indicated, the anti-PD-1 antibodys can include any combination of one or more Kabat CDRs and/or Chothia CDRs, e.g., described in Table 1. In one embodiment, the following definitions are used for the anti-PD-1 antibodys described in Table 1: HCDR1 according to the combined CDR definitions of both Kabat and Chothia, and HCCDRs 2-3 and LCCDRs 1-3 according the CDR definition of Kabat. Under all definitions, each VH and VL typically includes three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows. To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol.48:444-453 ) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used unless otherwise specified) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5. The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The nucleic acid and protein sequences described herein can be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol.215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecule of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res.25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See www.ncbi.nlm.nih.gov. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Table 1. Amino acid and nucleotide sequences of exemplary anti-PD-1 antibodies

In a preferred embodiment, the anti PD-1 antibody for use in the combinations, methods and compositions of the invention comprises: (a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 5, a VHCDR2 amino acid sequence of SEQ ID NO: 6, and a VHCDR3 amino acid sequence of SEQ ID NO: 4; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 14, a VLCDR2 amino acid sequence of SEQ ID NO: 15, and a VLCDR3 amino acid sequence of SEQ ID NO: 16; (b) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 2; a VHCDR2 amino acid sequence of SEQ ID NO: 3; and a VHCDR3 amino acid sequence of SEQ ID NO: 4; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 11, a VLCDR2 amino acid sequence of SEQ ID NO: 12, and a VLCDR3 amino acid sequence of SEQ ID NO: 13; (c) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1; a VHCDR2 amino acid sequence of SEQ ID NO: 6; and a VHCDR3 amino acid sequence of SEQ ID NO: 4; and a a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 14; a VLCDR2 amino acid sequence of SEQ ID NO: 15; and a VLCDR3 amino acid sequence of SEQ ID NO: 16; or (d) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1; a VHCDR2 amino acid sequence of SEQ ID NO: 3; and a VHCDR3 amino acid sequence of SEQ ID NO: 4; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 11; a VLCDR2 amino acid sequence of SEQ ID NO: 12; and a VLCDR3 amino acid sequence of SEQ ID NO: 13. In another preferred embodiment, the anti PD-1 antibody for use in the combinations of the invention comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 21. In another preferred embodiment, the anti PD-1 antibody for use in the combinations of the invention comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 17. In another preferred embodiment, the anti PD-1 antibody for use in the combinations of the invention comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 23. In another preferred embodiment, the anti PD-1 antibody for use in the combinations of the invention comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 19. Other Exemplary anti-PD-1 antibodies for use in the combinations described herein In one embodiment, the anti-PD-1 antibody is Nivolumab (Bristol-Myers Squibb), also known as MDX-1106, MDX-1106-04, ONO-4538, BMS-936558, or OPDIVO®. Nivolumab (clone 5C4) and other anti-PD-1 antibodies are disclosed in US 8,008,449 and WO 2006/121168, incorporated by reference in their entirety. In one embodiment, the anti-PD-1 antibody comprises one or more of the CDR sequences (or collectively all of the CDR sequences), the heavy chain or light chain variable region sequence, or the heavy chain or light chain sequence of Nivolumab, e.g., as disclosed in Table 2. In one embodiment, the anti-PD-1 antibody is Pembrolizumab (Merck & Co), also known as Lambrolizumab, MK-3475, MK03475, SCH-900475, or KEYTRUDA®. Pembrolizumab and other anti-PD-1 antibodies are disclosed in Hamid, O. et al. (2013) New England Journal of Medicine 369 (2): 134–44, US 8,354,509, and WO 2009/114335, incorporated by reference in their entirety. In one embodiment, the anti-PD-1 antibody comprises one or more of the CDR sequences (or collectively all of the CDR sequences), the heavy chain or light chain variable region sequence, or the heavy chain or light chain sequence of Pembrolizumab, e.g., as disclosed in Table 2. In one embodiment, the anti-PD-1 antibody is Pidilizumab (CureTech), also known as CT-011. Pidilizumab and other anti-PD-1 antibodies are disclosed in Rosenblatt, J. et al. (2011) J Immunotherapy 34(5): 409-18, US 7,695,715, US 7,332,582, and US 8,686,119, incorporated by reference in their entirety. In one embodiment, the anti-PD-1 antibody comprises one or more of the CDR sequences (or collectively all of the CDR sequences), the heavy chain or light chain variable region sequence, or the heavy chain or light chain sequence of Pidilizumab, e.g., as disclosed in Table 2. In one embodiment, the anti-PD-1 antibody is MEDI0680 (Medimmune), also known as AMP-514. MEDI0680 and other anti-PD-1 antibodies are disclosed in US 9,205,148 and WO 2012/145493, incorporated by reference in their entirety. In one embodiment, the anti-PD-1 antibody comprises one or more of the CDR sequences (or collectively all of the CDR sequences), the heavy chain or light chain variable region sequence, or the heavy chain or light chain sequence of MEDI0680. In one embodiment, the anti-PD-1 antibody is REGN2810 (Regeneron). In one embodiment, the anti-PD-1 antibody comprises one or more of the CDR sequences (or collectively all of the CDR sequences), the heavy chain or light chain variable region sequence, or the heavy chain or light chain sequence of REGN2810. In one embodiment, the anti-PD-1 antibody is PF-06801591 (Pfizer). In one embodiment, the anti-PD-1 antibody comprises one or more of the CDR sequences (or collectively all of the CDR sequences), the heavy chain or light chain variable region sequence, or the heavy chain or light chain sequence of PF-06801591. In one embodiment, the anti-PD-1 antibody is BGB-A317 or BGB-108 (Beigene). In one embodiment, the anti-PD-1 antibody comprises one or more of the CDR sequences (or collectively all of the CDR sequences), the heavy chain or light chain variable region sequence, or the heavy chain or light chain sequence of BGB-A317 or BGB-108. In one embodiment, the anti-PD-1 antibody is INCSHR1210 (Incyte), also known as INCSHR01210 or SHR-1210. In one embodiment, the anti-PD-1 antibody comprises one or more of the CDR sequences (or collectively all of the CDR sequences), the heavy chain or light chain variable region sequence, or the heavy chain or light chain sequence of INCSHR1210. In one embodiment, the anti-PD-1 antibody is TSR-042 (Tesaro), also known as ANB011. In one embodiment, the anti-PD-1 antibody comprises one or more of the CDR sequences (or collectively all of the CDR sequences), the heavy chain or light chain variable region sequence, or the heavy chain or light chain sequence of TSR-042. Further known anti-PD-1 antibodies include those described, e.g., in WO 2015/112800, WO 2016/092419, WO 2015/085847, WO 2014/179664, WO 2014/194302, WO 2014/209804, WO 2015/200119, US 8,735,553, US 7,488,802, US 8,927,697, US 8,993,731, and US 9,102,727, incorporated by reference in their entirety. In one embodiment, the anti-PD-1 antibody is an antibody that competes for binding with, and/or binds to the same epitope on PD-1 as, one of the anti-PD-1 antibodies described herein. Table 2. Amino acid sequences of other exemplary anti-PD-1 antibodys

Dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I), in combination with an anti-PD-1 antibody, can be the administration of compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks during a cycle period, with administration of the anti-PD-1 antibody once every two weeks, once every three weeks or once every four weeks during a cycle period. Such administration of the compound of Formula (I) and the anti-PD-1 antibody can occur for 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 cycle periods. In addition, the administration of the ant-PD-1 antibody continues to occur for one or more cycle periods after the final administration of the compound of Formula (I). A cycle period is the number and timing, or recommended repetitions, of therapy and are usually expressed as the number of days. Examples of a cycle period can be every 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. By way of example, compound of Formula (I) is administered intratumorally on Day 1 and Day 15 of one or more 28 day cycle periods, while the anti-PD-1 antibody is administered on Day 1 of each 28 day cycle period. Alternatively, compound of Formula (I) is administered intratumorally on Day 1 and Day 15 of one or more 28 day cycle periods, while the anti-PD-1 antibody is administered on Day 1 of each 28 day cycle period and is further administered on Day 1 of one or more 28 day cycle periods after the final administration of the compouund of Formula (I). A dosing schedule can include a dose delay (drug holiday), wherein the compound of Formula (I) is not administered during one or more cycle periods. Such dose delays correspond to the cycle period and can be for 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days to 31 days. Accordingly, for a dosing schedule which includes a dose delay, compound of Formula (I) is first administered during one or more cycle periods, then compound of Formula (I) is not administered during one or more subsequent cycle periods, and then compound of Formula (I) is again administered during one or more additional cycle periods. Alternatively, for a dosing schedule which includes a dose delay, compound of Formula (I) is first administered during one or more cycle periods, then compound of Formula (I) is not administered during one or more subsequent cycle periods (dose delay). By way of example, during a nine cycle period dosing schedule with dose delay, the anti- PD-1 antibody is administered in each of cycles 1 to 9, whereas the compound of Formula (I) is administered intratumorally during cycles 1, 3, 5, 7 and 9, with a dose delay during cycles 2, 4, 6, and 8 wherein compound of Formula (I) is not administered. In this example, the dosing schedule comprises nine cycle periods in which the compound of Formula (I) is administered intratumorally for five cycle periods with four dose delays, wherein each dose delay is for one cycle period occurring between each cycle period in which compound of Formula (I) is administered. During this nine cycle period dosing schedule the anti-PD-1 antibody is administered in each of cycles 1 to 9 with no dose delay for the anti-PD-1 antibody. Alternatively, during an eight cycle period dosing schedule the anti-PD-1 antibody is administered in each of cycles 1 to 8, whereas the compound of Formula (I) is administered intratumorally during cycles 1, 2, 4, 5, 7 and 8, with a dose delay during cycles 3 and 6 wherein compound of Formula (I) is not administered. In this example, the dosing schedule comprises eight cycle periods in which the compound of Formula (I) is administered intratumorally for six cycle periods with two dose delays, wherein each dose delay is for one cycle period and the compound of Formula (I) is administered for two consecutive cycle periods before the dose delay. During this eight cycle period dosing schedule the anti-PD-1 antibody is administered in each of cycles 1 to 8 with no dose delay for the anti-PD-1 antibody. In addition, during a six cycle period dosing schedule the anti-PD-1 antibody is administered in each of cycles 1 to 6 whereas the compound of Formula (I) is administered intratumorally during cycles 1, 2, 5 and 6, with a dose delay during cycles 3 and 4 wherein compound of Formula (I) is not administered. In this example, the dosing schedule comprises six cycle periods in which the compound of Formula (I) is administered intratumorally for four cycle periods with a dose delay for two consecutive cycle periods, wherein the compound of Formula (I) is administered for two consecutive cycle periods before the dose delay. During this six cycle period dosing schedule the anti-PD-1 antibody is administered in each of cycles 1 to 6 with no dose delay for the anti-PD-1 antibody. Alternatively, during a six cycle period dosing schedule the anti-PD-1 antibody is administered in each of cycles 1 to 6 whereas the compound of Formula (I) is administered intratumorally during cycles 1, 2, 5 and 6, with a dose delay during cycles 3 and 4 wherein compound of Formula (I) is not administered. Then the anti-PD-1 antibody is administered for one or more cycles after cycle 6. In this example, the dosing schedule comprises six cycle periods in which the compound of Formula (I) is administered intratumorally for four cycle periods with a dose delay for two consecutive cycle periods, wherein the compound of Formula (I) is administered for two consecutive cycle periods before the dose delay. During this six cycle period dosing schedule the anti-PD-1 antibody is administered in each of cycles 1 to 6, and for one or more additional cycle periods, with no dose delay for the anti-PD-1 antibody. In certain embodiments of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg, while the anti-PD-1 antibody is administered once a week to once every 2, 3 or 4 weeks at a dose of about 1 to 30 mg/kg or at a flat dose of about 200 mg to about 500 mg. In certain embodiments of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, once a week, once every two weeks, once every three weeks or once every four weeks, and the anti- PD-1 antibody is administered by injection (e.g., subcutaneously or intravenously) once a week to once every 2, 3 or 4 weeks at a dose of about 1 to 30 mg/kg, about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 1 to 5 mg/kg, or about 3 mg/kg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is administered intravenously every other week at a dose from about 10 to 20 mg/kg. In another embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is administered intravenously every 4 weeks at a dose from about 1 to 10 mg/kg, or from about 1 to 5 mg/kg or about 3 mg/kg. In another embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is administered intravenously every 3 weeks at a dose from about 1 to 10 mg/kg, or from about 1 to 5 mg/kg or about 3 mg/kg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is administered intravenously once a week to once every 2, 3 or 4 weeks at a flat dose of about 200 mg to 500 mg, about 250 mg to 450 mg, about 300 mg to 400 mg, about 250 mg to 350 mg, about 350 mg to 450 mg, or about 300 mg or about 400 mg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once every two weeks at a dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is administered intravenously once every three weeks or once every four weeks at a dose from about 300 mg to 400 mg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once every two weeks at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is administered intravenously once every three weeks at a flat dose of about 300 mg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once every two weeks at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is administered intravenously every four weeks at a flat dose of about 400 mg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once every two weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is administered intravenously once every three weeks at a flat dose of about 300 mg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once every two weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is administered intravenously every four weeks at a flat dose of about 400 mg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once every two weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is administered intravenously once every three weeks at a flat dose of about 300 mg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once every two weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is administered intravenously every four weeks at a flat dose of about 400 mg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once every two weeks at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is administered intravenously once every four weeks at a flat dose of about 300 mg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once every two weeks at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is administered intravenously every three weeks at a flat dose of about 400 mg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once every two weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is administered intravenously once every four weeks at a flat dose of about 300 mg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once every two weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is administered intravenously every three weeks at a flat dose of about 400 mg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once every two weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is administered intravenously once every four weeks at a flat dose of about 300 mg. In one embodiment of the dosing regimens (i.e dosing schedules) for the administration of a compound of Formula (I) in combination with an anti-PD-1 antibody, the compound of Formula (I)) is intratumorally administered once every two weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is administered intravenously every three weeks at a flat dose of about 400 mg. Certain aspects and examples of dosage and dosing regimens (therapeutic regimen) for the compound of Formula (I) in combination with an anti-PD-1 antibody are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the such dosage and dosage regimens used to treat solid tumors. Embodiment 267. A therapeutic regimen for treating a solid tumor, comprising intratumorally administering a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg and administering an anti-PD-1 antibody at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Embodiment 268. The therapeutic regimen of Embodiment 267, wherein the anti-PD-1 antibody is administered intravenously. Embodiment 269. The therapeutic regimen of Embodiment 267, wherein the anti-PD-1 antibody is administered subcutaneously. Embodiment 270. The therapeutic regimen for treating a solid tumor of any one of Embodiments 267 to 269, wherein the anti-PD-1 antibody is selected from the group consisting of spartalizumab, nivolumab, pembrolizumab, pidilizumab and AMP-224. Embodiment 271. The therapeutic regimen for treating a solid tumor of any one of Embodiments 267 to 270, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 272. A therapeutic regimen for treating a solid tumor, wherein the therapeutic regimen comprises intratumorally administering a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg, and intravenously administering an anti-PD-1 antibody either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 273. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 274. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 275. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 276. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 277. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 278. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 279. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 280. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 281. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 282. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 283. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 284. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 285. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 286. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 287. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 288. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 289. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 290. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 291. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 292. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 293. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 294. The therapeutic regimen for treating a solid tumor of Embodiment 272, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 295. The therapeutic regimen for treating a solid tumor of any one of Embodiments 272 to 294, wherein the compound of Formula (I) is intratumorally administered for one or more cycle periods and the anti-PD-1 antibody is intravenously administered for one or more cycle periods, and wherein the anti-PD-1 antibody is spartalizumab. Embodiment 296. The therapeutic regimen for treating a solid tumor of any one of Embodiments 272 to 295, wherein the compound of Formula (I) is intratumorally administered for two or more cycle periods and the anti-PD-1 antibody is intravenously administered for two or more cycle periods, and wherein the anti-PD-1 antibody is spartalizumab. Embodiment 297. The therapeutic regimen for treating a solid tumor of any one of Embodiments 272 to 296, further comprising one or more dose delays for the compound of Formula (I), wherein each dose delay is for one or more cycle periods. Embodiment 298. The therapeutic regimen for treating a solid tumor of any one of Embodiments 272 to 296, further comprising one or more dose delays for the compound of Formula (I), wherein each dose delay is for one cycle period. Embodiment 299. The therapeutic regimen for treating a solid tumor of any one of Embodiments 272 to 296, further comprising one or more dose delays for the compound of Formula (I), wherein each dose delay is for two or more consecutive cycle periods. Embodiment 300. The therapeutic regimen for treating a solid tumor of any one of Embodiments 272 to 296, further comprising one or more dose delays for the compound of Formula (I), wherein each dose delay is for two consecutive cycle periods. Embodiment 301. The therapeutic regimen for treating a solid tumor of any one of Embodiments 272 to 296, further comprising a dose delay for the compound of Formula (I), wherein the dose delay is for two consecutive cycle periods and the compound of Formula (I) is intratumorally administered for two consecutive cycle periods before the dose delay. Embodiment 302. The therapeutic regimen for treating a solid tumor of any one of Embodiments 272 to 296, further comprising a dose delay for the compound of Formula (I), wherein the dose delay is for two consecutive cycle periods, and wherein the compound of Formula (I) is intratumorally administered for two consecutive cycle periods before the dose delay, and the compound of Formula (I) is intratumorally administered for two consecutive cycle periods after the dose delay. Embodiment 303. The therapeutic regimen for treating a solid tumor of Embodiment 302, wherein the therapeutic regimen further comprises intravenously administering the anti-PD- 1 antibody for one or more cycle periods after the additional administration of the compound of Formula (I), wherein the anti-PD-1 antibody is spartalizumab. Embodiment 304. The therapeutic regimen for treating a solid tumor of any one of Embodiments 272 to 301, wherein the compound of Formula (I) is intratumorally administered for two consecutive cycle periods, followed by a dose delay for two consecutive cycle periods, followed by additional administration of the compound of Formula (I) for two consecutive cycle periods, followed by additional intravenous administration of the anti-PD-1 antibody for one or more cycle periods, wherein the anti-PD- 1 antibody is spartalizumab. Embodiment 305. The therapeutic regimen of any one of Embodiments 295 to 304, wherein each cycle period is 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 306. The therapeutic regimen of any one of Embodiments 295 to 305, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 307. The therapeutic regimen of any one of Embodiments 295 to 306, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days or 28 days. Embodiment 308. The therapeutic regimen of any one of Embodiments 295 to 307, wherein each cycle period is 28 days. Embodiment 309. A therapeutic regimen for treating a solid tumor, wherein the therapeutic regimen has a six cycle period dosing schedule comprising: a) intratumorally administering a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and b) intravenously administering an anti-PD-1 antibody for each of the six cycle periods; and wherein: each cycle period is 28 days; the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6, and the anti-PD-1 antibody is spartalizumab which is intravenously administered at a flat dose of 400 mg on Day 1 of Cycles 1, 2, 3, 4, 5 and 6. Embodiment 310. The therapeutic regimen for treating a solid tumor of Embodiment 309, wherein the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 311. The therapeutic regimen for treating a solid tumor of Embodiment 309, wherein the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 312. The therapeutic regimen for treating a solid tumor of Embodiment 309, wherein the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 313. The therapeutic regimen for treating a solid tumor of Embodiment 309, wherein the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 314. A therapeutic regimen for treating a solid tumor, wherein the therapeutic regimen has a six cycle period dosing schedule comprising: a) intratumorally administering a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and b) intravenously administering an anti-PD-1 antibody for each of the six cycle periods; and wherein: each cycle period is 28 days; the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6, and the anti-PD-1 antibody spartalizumab which is intravenously administered at a flat dose of 400 mg on Day 1 of Cycles 1, 2, 3, 4, 5 and 6. Embodiment 315. A therapeutic regimen for treating a solid tumor, wherein the therapeutic regimen has a six cycle period dosing schedule comprising: a) intratumorally administering a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and b) intravenously administering an anti-PD-1 antibody for each of the six cycle periods; and wherein: each cycle period is 28 days; the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6, and the anti-PD-1 antibody is spartalizumab which is intravenously administered at a flat dose of 400 mg on Day 1 of Cycles 1, 2, 3, 4, 5 and 6. Embodiment 316. The therapeutic regimen of any one of Embodiments 309 to 315, wherein the therapeutic regimen further comprises intravenously administering the the anti-PD-1 antibody for one or more additional cycle periods after Cycle 6. The invention further provides a method of treating a solid tumor in a subject in need thereof using such dosage and dosage regimens, wherein the method comprises intratumorally administering a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg , and administering an anti-PD-1 antibody at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Certain aspects and examples of such methods using a compound of Formula (I) in combination with an anti-PD-1 antibody are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of such methods to treat solid tumors. Embodiment 317. A method for treating a solid tumor in a subject in need thereof, comprising intratumorally administering a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg, and administering an anti-PD-1 antibody at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Embodiment 318. The therapeutic regimen of Embodiment 317, wherein the anti-PD-1 antibody is administered intravenously. Embodiment 319. The therapeutic regimen of Embodiment 317, wherein the anti-PD-1 antibody is administered subcutaneously. Embodiment 320. The therapeutic regimen for treating a solid tumor of any one of Embodiments 317 to 319, wherein the anti-PD-1 antibody is selected from the group consisting of spartalizumab, nivolumab, pembrolizumab, pidilizumab and AMP-224. Embodiment 321. The therapeutic regimen for treating a solid tumor of any one of Embodiments 317 to 320, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 322. A method for treating a solid tumor in a subject in need thereof, comprising intratumorally administering a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg, and intravenously administering an anti-PD-1 antibody either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 323. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 324. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 325. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 326. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 327. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once a week at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 328. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 329. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 330. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 331. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 332. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 333. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 334. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 335. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 336. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 337. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 338. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 339. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every three weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 340. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 341. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 342. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 343. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 344. The method for treating a solid tumor of Embodiment 322, wherein the compound of Formula (I) is intratumorally administered once every four weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 345. The method of any one of Embodiments 322 to 344, wherein the compound of Formula (I) is intratumorally administered in a therapeutically effective amount. Embodiment 346. The method of any one of Embodiments 322 to 345, wherein the compound of Formula (I) is intratumorally administered for one or more cycle periods and the anti-PD-1 antibody is intravenously administered for one or more cycle periods, and wherein the anti- PD-1 antibody is spartalizumab. Embodiment 347. The method of any one of Embodiments 322 to 346, wherein the compound of Formula (I) is intratumorally administered for two or more cycle periods and the anti-PD-1 antibody is intravenously administered for two or more cycle periods, and wherein the anti- PD-1 antibody is spartalizumab. Embodiment 348. The method of any one of Embodiments 322 to 347, further comprising one or more dose delays for the compound of Formula (I), wherein each dose delay is for one or more cycle periods. Embodiment 349. The method of any one of Embodiments 322 to 347, further comprising one or more dose delays for the compound of Formula (I), wherein each dose delay is for one cycle period. Embodiment 350. The method of any one of Embodiments 322 to 347, further comprising one or more dose delays for the compound of Formula (I), wherein each dose delay is for two or more consecutive cycle periods. Embodiment 351. The method of any one of Embodiments 322 to 347, further comprising one or more dose delays for the compound of Formula (I), wherein each dose delay is for two consecutive cycle periods. Embodiment 352. The method of any one of Embodiments 322 to 347, further comprising a dose delay for the compound of Formula (I), wherein the dose delay is for two consecutive cycle periods and the compound of Formula (I) is administered for two consecutive cycle periods before the dose delay. Embodiment 353. The method of any one of Embodiments 322 to 347, further comprising a dose delay for the compound of Formula (I), wherein the dose delay is for two consecutive cycle periods, and wherein the compound of Formula (I) is intratumorally administered for two consecutive cycle periods before the dose delay, and the compound of Formula (I) is intratumorally administered for two consecutive cycle periods after the dose delay Embodiment 354. The method of any one of Embodiments 322 to 353, wherein the therapeutic regimen further comprises intravenously administering the anti-PD-1 antibody for one or more cycle periods after the additional administration of the compound of Formula (I), wherein the anti-PD-1 antibody is spartalizumab. Embodiment 355. The method of any one of Embodiments 322 to 352, wherein the compound of Formula (I) is intratumorally administered for two consecutive cycle periods, followed by a dose delay for two consecutive cycle periods, followed by additional administration of the compound of Formula (I) for two consecutive cycle periods, followed by additional intravenous administration of the anti-PD-1 antibody for one or more cycle periods, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 356. The method of any one of Embodiments 346 to 355, wherein each cycle period is 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 357. The method of any one of Embodiments 346 to 356, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 358. The method of any one of Embodiments 346 to 357, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days or 28 days. Embodiment 359. The method of any one of Embodiments 346 to 358, wherein each cycle period is 28 days. The invention further provides the use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is administered at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Certain aspects and examples of such uses of a compound of Formula (I) in combination with an ant-PD-1 antibody are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of such uses to treat solid tumors. Embodiment 360. Use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is administered at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Embodiment 361. The use of the compound of Formula (I) of Embodiment 360, wherein the anti-PD-1 antibody is administered intravenously. Embodiment 362. The use of the compound of Formula (I) of Embodiment 360, wherein the anti-PD-1 antibody is administered subcutaneously. Embodiment 363. The use of the compound of Formula (I) of any one of Embodiments 360 to 362, wherein the anti-PD-1 antibody is selected from the group consisting of spartalizumab, nivolumab, pembrolizumab, pidilizumab and AMP-224. Embodiment 364. The use of the compound of Formula (I) of any one of Embodiments 360 to 363, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 365. Use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor, wherein the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 366. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 367. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 368. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 369. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 370. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once a week at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 371. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 372. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 373. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 374. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 375. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 376. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 377. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 378. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 379. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 380. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 381. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 382. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every three weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 383. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 384. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 385. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 386. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 387. The use of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 365, wherein the compound of Formula (I) is administered intratumorally once every four weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. The invention further provides a combination comprising a compound of Formula (I) and an anti-PD-1 antibody for the use in the treatment of a solid tumor, wherein the compound of Formula (I) is at a flat dose of about 100 µg to about 600 µg and the anti-PD-1 antibody is at a dose selected from the group consisting of i) about 300 mg; ii) about 400 mg; iii) about 240 mg; iv) about 480 mg; v) about 200 mg; and vi) about 10 mg/kg. Certain aspects and examples of such uses of a compound of Formula (I) are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of such uses to treat solid tumors. Embodiment 388. A combination comprising a compound of Formula (I) and an anti-PD-1 antibody for the use in the treatment of a solid tumor, wherein the compound of Formula (I) is at a flat dose of about 100 µg to about 600 µg and the anti-PD-1 antibody is at a dose selected from the group consisting of i) about 300 mg; ii) about 400 mg; iii) about 240 mg; iv) about 480 mg; v) about 200 mg; and vi) about 10 mg/kg. Embodiment 389. The combination of Embodiment 388, wherein the anti-PD-1 antibody is administered intravenously. Embodiment 390. The combination of Embodiment 388, wherein the anti-PD-1 antibody is administered subcutaneously. Embodiment 391. The combination of any one of Embodiments 388 to 390, wherein the anti- PD-1 antibody is selected from the group consisting of spartalizumab, nivolumab, pembrolizumab, pidilizumab and AMP-224. Embodiment 392. The combination of any one of Embodiments 388 to 391, wherein the anti- PD-1 antibody is spartalizumab. Embodiment 393. A combination comprising a compound of Formula (I) and an anti-PD-1 antibody for the use in the treatment of a solid tumor, wherein the compound of Formula (I) is at a flat dose of about 100 µg to about 600 µg and the anti-PD-1 antibody is at a flat dose of about 300 mg or about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 394. The combination of Embodiment 393, wherein the compound of Formula (I) is at a flat dose of about 200 µg to about 600 µg and the anti-PD-1 antibody is at a flat dose of about 300 mg or about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 395. The combination of Embodiment 393, wherein the compound of Formula (I) is at a flat dose of about 400 µg to about 600 µg and the anti-PD-1 antibody is at a flat dose of about 300 mg or about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 396. The combination of Embodiment 393, wherein the compound of Formula (I) is at a flat dose of about 400 µg and the anti-PD-1 antibody is at a flat dose of about 300 mg or about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 397. The combination of Embodiment 393, wherein the compound of Formula (I) is at a flat dose of about 400 µg and the anti-PD-1 antibody is at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 398. The combination of Embodiment 393, wherein the compound of Formula (I) is at a flat dose of about 600 µg and the anti-PD-1 antibody is at a flat dose of about 300 mg or about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 399. The combination of Embodiment 393, wherein the compound of Formula (I) is at a flat dose of about 600 µg and the anti-PD-1 antibody is at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. The invention also provides dosage and dosing regimens for pharmaceutical composition comprising a compound of Formula (I) used in combination with an anti-PD-1 antibody for the treatment of solid tumors. Certain aspects and examples of such dosage and dosing regimens (therapeutic regimen) are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the such dosage and dosage regimens used to treat solid tumors. Embodiment 400. A therapeutic regimen for treating a solid tumor, comprising (a) intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and (b) administering an anti- PD-1 antibody at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Embodiment 401. The therapeutic regimen of Embodiment 400, wherein the anti-PD-1 antibody is administered intravenously. Embodiment 402. The therapeutic regimen of Embodiment 400, wherein the anti-PD-1 antibody is administered subcutaneously. Embodiment 403. The therapeutic regimen of any one of Embodiments 400 to 402, wherein the anti-PD-1 antibody is selected from the group consisting of spartalizumab, nivolumab, pembrolizumab, pidilizumab and AMP-224. Embodiment 404. The therapeutic regimen for treating a solid tumor of any one of Embodiments 400 to 403, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 405. A therapeutic regimen for treating a solid tumor, comprising (a) intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and (b) intravenously administering an anti-PD-1 antibody either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 406. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 407. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 408. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 409. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and (b) the anti-PD- 1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD- 1 antibody is spartalizumab. Embodiment 410. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and (b) the anti-PD- 1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD- 1 antibody is spartalizumab. Embodiment 411. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 412. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 413. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 414. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 415. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and (b) the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 416. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 417. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 418. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 419. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 420. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 421. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 422. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 423. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 424. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 425. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 426. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 427. The therapeutic regimen for treating a solid tumor of Embodiment 405, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and (b) the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 428. The therapeutic regimen of any one of Embodiments 405 to 427, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for one or more cycle periods and the anti-PD-1 antibody is intravenously administered for one or more cycle periods, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 429. The therapeutic regimen of any one of Embodiments 405 to 428, wherein intratumoral administration of the pharmaceutical composition comprising the compound of Formula (I) is for two or more cycle periods and the intravenous administration of the anti- PD-1 antibody is for two or more cycle periods, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 430. The therapeutic regimen of any one of Embodiments 405 to 429, further comprising one or more dose delays for the pharmaceutical composition comprising the compound of Formula (I), wherein each dose delay is for one or more cycle periods. Embodiment 431. The therapeutic regimen of any one of Embodiments 405 to 429, further comprising one or more dose delays for the pharmaceutical composition comprising the compound of Formula (I), wherein each dose delay is for one cycle period. Embodiment 432. The therapeutic regimen of any one of Embodiments 405 to 429, further comprising one or more dose delays for the pharmaceutical composition comprising the compound of Formula (I), wherein each dose delay is for two or more consecutive cycle periods. Embodiment 433. The therapeutic regimen of any one of Embodiments 405 to 429, further comprising one or more dose delays for the pharmaceutical composition comprising the compound of Formula (I), wherein each dose delay is for two consecutive cycle periods. Embodiment 434. The therapeutic regimen of any one of Embodiments 405 to 429, further comprising a dose delay for the pharmaceutical composition comprising the compound of Formula (I), wherein the dose delay is for two consecutive cycle periods and the pharmaceutical composition comprising the compound of Formula (I) is administered for two consecutive cycle periods before the dose delay. Embodiment 435. The therapeutic regimen of any one of Embodiments 405 to 429, further comprising a dose delay for the pharmaceutical composition comprising the compound of Formula (I), wherein the dose delay is for two consecutive cycle periods, and wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for two consecutive cycle periods before the dose delay, and the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for two consecutive cycle periods after the dose delay. Embodiment 436. The therapeutic regimen of Embodiment 435, wherein the therapeutic regimen further comprises intravenously administering the anti-PD-1 antibody for one or more cycle periods after the additional administration of the pharmaceutical composition comprising the compound of Formula (I), wherein the anti-PD-1 antibody is spartalizumab. Embodiment 437. The therapeutic regimen of any one of Embodiments 405 to 434, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for two consecutive cycle periods, followed by a dose delay for two consecutive cycle periods, followed by additional administration of the pharmaceutical composition comprising the compound of Formula (I) for two consecutive cycle periods, followed by additional intravenous administration of the anti-PD-1 antibody for one or more cycle periods, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 438. The therapeutic regimen of any one of Embodiments 428 to 437, wherein each cycle period is 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 439. The therapeutic regimen of any one of Embodiments 428 to 438, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 440. The therapeutic regimen of any one of Embodiments 428 to 439, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days or 28 days. Embodiment 441. The therapeutic regimen of any one of Embodiments 428 to 440, wherein each cycle period is 28 days. Embodiment 442. A therapeutic regimen for treating a solid tumor, wherein the therapeutic regimen has a six cycle period dosing schedule comprising: a) intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the pharmaceutical composition comprising the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and b) intravenously administering an anti-PD-1 antibody for each of the six cycle periods; and wherein: each cycle period is 28 days; the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6, and the anti-PD-1 antibody is spartalizumab which is intravenously administered at a flat dose of 400 mg on Day 1 of Cycles 1, 2, 3, 4, 5 and 6. Embodiment 443. The therapeutic regimen for treating a solid tumor of Embodiment 442, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 444. The therapeutic regimen for treating a solid tumor of Embodiment 442, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg. Embodiment 445. The therapeutic regimen for treating a solid tumor of Embodiment 442, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg. Embodiment 446. The therapeutic regimen for treating a solid tumor of Embodiment 442, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg. Embodiment 447. The therapeutic regimen for treating a solid tumor of Embodiment 442, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg. Embodiment 448. A therapeutic regimen for treating a solid tumor, wherein the therapeutic regimen has a six cycle period dosing schedule comprising: a) intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the pharmaceutical composition comprising the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and b) intravenously administering an anti-PD-1 antibody for each of the six cycle periods; and wherein: each cycle period is 28 days; the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6, and the anti-PD-1 antibody is spartalizumab which is intravenously administered at a flat dose of 400 mg on Day 1 of Cycles 1, 2, 3, 4, 5 and 6. Embodiment 449. A therapeutic regimen for treating a solid tumor, wherein the therapeutic regimen has a six cycle period dosing schedule comprising: a) intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the pharmaceutical composition comprising the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and b) intravenously administering an anti-PD-1 antibody for each of the six cycle periods; and wherein: each cycle period is 28 days; the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6, and the anti-PD-1 antibody is spartalizumab which is intravenously administered at a flat dose of 400 mg on Day 1 of Cycles 1, 2, 3, 4, 5 and 6. Embodiment 450. The therapeutic regimen of any one of Embodiments 442 to 449, wherein the therapeutic regimen further comprises intravenously administering the anti-PD-1 antibody for one or more additional cycle periods after Cycle 6. The invention further provides a method of treating a solid tumor in a subject in need thereof using such dosage and dosage regimens described herein, wherein the method comprises (a) intratumorally administering pharmaceutical composition comprising a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg , and (b) administering an anti-PD-1 antibody at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Certain aspects and examples of such methods using a pharmaceutical composition comprising a compound of Formula (I) in combination with an anti-PD-1 antibody are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of such methods to treat solid tumors. Embodiment 451. A method for treating a solid tumor in a subject in need thereof, comprising (a) intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and (b) administering an anti- PD-1 antibody at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Embodiment 452. The method for treating a solid tumor of Embodiment 451, wherein the anti- PD-1 antibody is administered intravenously. Embodiment 453. The method for treating a solid tumor of Embodiment 451, wherein the anti- PD-1 antibody is administered subcutaneously. Embodiment 454. The method for treating a solid tumor of any one of Embodiments 451 to 453, wherein the anti-PD-1 antibody is selected from the group consisting of spartalizumab, nivolumab, pembrolizumab, pidilizumab and AMP-224. Embodiment 455. The method for treating a solid tumor of any one of Embodiments 451 to 454, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 456. A method for treating a solid tumor in a subject in need thereof, comprising (a) intratumorally administering a pharmaceutical composition comprising a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and (b) intravenously administering an anti-PD-1 antibody either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 457. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and the anti-PD- 1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 458. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg, and the anti-PD- 1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 459. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg, and the anti-PD- 1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 460. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 461. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 462. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 463. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 464. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 465. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 466. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg. Embodiment 467. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 468. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg.. Embodiment 469. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 470. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 471. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 472. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 473. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 474. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 475. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 476. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 477. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 478. The method for treating a solid tumor of Embodiment 456, wherein the pharmaceutical composition comprising a compound of Formula (I) is intratumorally administered once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg. Embodiment 479. The method for treating a solid tumor of any one of Embodiments 451 to 478, wherein the pharmaceutical composition comprises a therapeutically effective amount of the compound of Formula (I). Embodiment 480. The method of any one of Embodiments 456 to 479, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for one or more cycle periods and the anti-PD-1 antibody is intravenously administered for one or more cycle periods, and wherein the anti-PD-1 antibody is spartalizumab. Embodiment 481. The method of any one of Embodiments 456 to 480, wherein the intratumoral administration of the pharmaceutical composition comprising the compound of Formula (I) is for two or more cycle periods and the intravenous administration of the anti- PD-1 antibody is for two or more cycle periods. Embodiment 482. The method of any one of Embodiments 456 to 481, further comprising one or more dose delays for the pharmaceutical composition comprising the compound of Formula (I), wherein each dose delay is for one or more cycle periods. Embodiment 483. The method of any one of Embodiments 456 to 481, further comprising one or more dose delays for the pharmaceutical composition comprising the compound of Formula (I), wherein each dose delay is for one cycle period. Embodiment 484. The method of any one of Embodiments 456 to 481, further comprising one or more dose delays for the pharmaceutical composition comprising the compound of Formula (I), wherein each dose delay is for two or more consecutive cycle periods. Embodiment 485. The method of any one of Embodiments 456 to 481, further comprising one or more dose delays for the pharmaceutical composition comprising the compound of Formula (I), wherein each dose delay is for two consecutive cycle periods. Embodiment 486. The method of any one of Embodiments 456 to 481, further comprising a dose delay for the pharmaceutical composition comprising the compound of Formula (I), wherein the dose delay is for two consecutive cycle periods and the pharmaceutical composition comprising the compound of Formula (I) is administered for two consecutive cycle periods before the dose delay. Embodiment 487. The method of any one of Embodiments 456 to 481, further comprising a dose delay for the pharmaceutical composition comprising the compound of Formula (I), wherein the dose delay is for two consecutive cycle periods, and wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for two consecutive cycle periods before the dose delay, and the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for two consecutive cycle periods after the dose delay. Embodiment 488. The method of any one of Embodiments 456 to 487, wherein the method further comprises intravenously administering the anti-PD-1 antibody for one or more cycle periods after the additional intratumoral administration of the pharmaceutical composition comprising the compound of Formula (I) . Embodiment 489. The method of any one of Embodiments 456 to 486, wherein the pharmaceutical composition comprising the compound of Formula (I) is intratumorally administered for two consecutive cycle periods, followed by a dose delay for two consecutive cycle periods, followed by additional intratumoral administration of the pharmaceutical composition comprising the compound of Formula (I) for two consecutive cycle periods, followed by additional intravenous administration of the anti-PD-1 antibody for one or more cycle periods. Embodiment 490. The method of any one of Embodiments 480 to 489, wherein each cycle period is 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 491. The method of any one of Embodiments 480 to 490, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days. Embodiment 492. The method of any one of Embodiments 480 to 491, wherein each cycle period is 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days or 28 days. Embodiment 493. The method of any one of Embodiments 480 to 492, wherein each cycle period is 28 days. The invention further provides the use of pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is administered at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Certain aspects and examples of such uses of a compound of Formula (I) in combination with an anti-PD-1 antibody are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of such uses to treat solid tumors. Embodiment 494. Use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and the anti-PD- 1 antibody is administered at a dosing schedule selected from the group consisting of i) once every three weeks at a flat dose of about 300 mg; ii) once every four weeks at a flat dose of about 400 mg; iii) once every two weeks at a flat dose of about 240 mg; iv) once every four weeks at a flat dose of about 480 mg; v) once every two weeks at a flat dose of about 200 mg; vi) once every three weeks at a flat dose of about 200 mg; and vii) once every two weeks at a dose of about 10 mg/kg. Embodiment 495. The use of a pharmaceutical composition comprising a compound of Formula (I) and the use of an anti-PD-1 antibody of Embodiment 494, wherein the anti-PD-1 antibody is administered intravenously. Embodiment 496. The use of a pharmaceutical composition comprising a compound of Formula (I) and the use of an anti-PD-1 antibody of Embodiment 494, wherein the anti-PD-1 antibody is administered subcutaneously. Embodiment 497. The use of a pharmaceutical composition comprising a compound of Formula (I) and the use of an anti-PD-1 antibody of any one of Embodiments 494 to 496, wherein the anti-PD-1 antibody is selected from the group consisting of spartalizumab, nivolumab, pembrolizumab, pidilizumab and AMP-224. Embodiment 498. The use of a pharmaceutical composition comprising a compound of Formula (I) and the use of an anti-PD-1 antibody of any one of Embodiments 494 to 497, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 499. Use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once a week, once every two weeks, once every three weeks or once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 500. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 501. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 502. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 503. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 504. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once a week in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 505. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 506. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 507. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 508. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 509. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 510. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 511. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every two weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 512. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 513. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 514. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 515. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 516. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every three weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 517. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 518. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 519. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 520. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 521. The use of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody for the treatment of a solid tumor of Embodiment 499, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally once every four weeks in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. The invention further provides a combination comprising a pharmaceutical composition comprising a compound of Formula (I) and an anti-PD-1 antibody for the use in the treatment of a solid tumor, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg and the anti-PD-1 antibody is administered at a dose selected from the group consisting of i) about 300 mg; ii) about 400 mg; iii) about 240 mg; iv) about 480 mg; v) about 200 mg; and vi) about 10 mg/kg. Certain aspects and examples of such uses of a pharmaceutical composition comprising a compound of Formula (I) in combination with the use of an anti-PD-1 antibody are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of such uses to treat solid tumors. Embodiment 522. A combination comprising a pharmaceutical composition comprising a compound of Formula (I) and an anti-PD-1 antibody for the use in the treatment of a solid tumor, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and the anti-PD- 1 antibody is administered at a dose selected from the group consisting of i) about 300 mg; ii) about 400 mg; iii) about 240 mg; iv) about 480 mg; v) about 200 mg; and vi) about 10 mg/kg. Embodiment 523. The combination for the use in the treatment of a solid tumor of Embodiment 522, wherein the anti-PD-1 antibody is administered intravenously. Embodiment 524. The combination for the use in the treatment of a solid tumor of Embodiment 522, wherein the anti-PD-1 antibody is administered subcutaneously. Embodiment 525. The combination for the use in the treatment of a solid tumor of any one of Embodiments 522 to 524, wherein the anti-PD-1 antibody is selected from the group consisting of spartalizumab, nivolumab, pembrolizumab, pidilizumab and AMP-224. Embodiment 526. The combination for the use in the treatment of a solid tumor of any one of Embodiments 522 to 525, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 527. A combination comprising a pharmaceutical composition comprising a compound of Formula (I) and an anti-PD-1 antibody for the use in the treatment of a solid tumor, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg, and the anti-PD- 1 antibody is intravenously administered at a flat dose of about 300 mg or about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 528. The combination comprising a pharmaceutical composition comprising a compound of Formula (I) and ,for the use in the treatment of a solid tumor of Embodiment 527, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 200 µg to about 600 µg, and the anti-PD- 1 antibody is intravenously administered at a flat dose of about 300 mg or about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 529. The combination comprising a pharmaceutical composition comprising a compound of Formula (I) and an anti-PD-1 antibody for the use in the treatment of a solid tumor of Embodiment 527, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered at a flat dose of about 300 mg or about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 530. The combination comprising a pharmaceutical composition comprising a compound of Formula (I) and an anti-PD-1 antibody for the use in the treatment of a solid tumor of Embodiment 527, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered at a flat dose of about 300 mg or about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 531. The combination comprising a pharmaceutical composition comprising a compound of Formula (I) and an anti-PD-1 antibody for the use in the treatment of a solid tumor of Embodiment 527, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab. Embodiment 532. The combination comprising a pharmaceutical composition comprising a compound of Formula (I) and an anti-PD-1 antibody for the use in the treatment of a solid tumor of Embodiment 527, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered at a flat dose of about 300 mg or about 400 mg. Embodiment 533. The combination comprising a pharmaceutical composition comprising a compound of Formula (I) and an anti-PD-1 antibody for the use in the treatment of a solid tumor of Embodiment 527, wherein the pharmaceutical composition comprising the compound of Formula (I) is administered intratumorally in a sufficient amount whereby the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered at a flat dose of about 400 mg. Embodiment 534. In any one of Embodiments 267 to 533, wherein the anti-PD-1 antibody comprises: (a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 5, a VHCDR2 amino acid sequence of SEQ ID NO: 6, and a VHCDR3 amino acid sequence of SEQ ID NO: 4; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 14, a VLCDR2 amino acid sequence of SEQ ID NO: 15, and a VLCDR3 amino acid sequence of SEQ ID NO: 16; (b) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 2; a VHCDR2 amino acid sequence of SEQ ID NO: 3; and a VHCDR3 amino acid sequence of SEQ ID NO: 4; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 11, a VLCDR2 amino acid sequence of SEQ ID NO: 12, and a VLCDR3 amino acid sequence of SEQ ID NO: 13; (c) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1; a VHCDR2 amino acid sequence of SEQ ID NO: 6; and a VHCDR3 amino acid sequence of SEQ ID NO: 4; and a a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 14; a VLCDR2 amino acid sequence of SEQ ID NO: 15; and a VLCDR3 amino acid sequence of SEQ ID NO: 16; or (d) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1; a VHCDR2 amino acid sequence of SEQ ID NO: 3; and a VHCDR3 amino acid sequence of SEQ ID NO: 4; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 11; a VLCDR2 amino acid sequence of SEQ ID NO: 12; and a VLCDR3 amino acid sequence of SEQ ID NO: 13. Embodiment 535. In any one of Embodiments 267 to 533, wherein the anti-PD-1 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 21. Embodiment 536. In any one of Embodiments 267 to 533, wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 23. Embodiment 537. In any one of Embodiments 267 to 536, wherein the solid tumor is a breast cancer tumor, a bladder cancer tumor, a head and neck cancer tumor, head and neck squamous cell carcinoma (HNSCC), a non-small cell lung cancer tumor, a small cell lung cancer tumor, a colorectal cancer tumor, a gastrointestinal stromal tumor, a gastroesophageal carcinoma, a renal cell cancer tumor, a prostate cancer tumor, a liver cancer tumor, a colon cancer tumor, a pancreatic cancer tumor, an ovarian cancer tumor, a lymphoma, a cutaneous T-cell lymphoma, a visceral tumor or melanoma. Embodiment 538. In any one of Embodiments 267 to 537, wherein the solid tumor is a breast cancer tumor, head and neck squamous cell carcinoma (HNSCC), a visceral tumor or melanoma. Embodiment 539. In any one of Embodiments 267 to 538, wherein the solid tumor is head and neck squamous cell carcinoma (HNSCC), a visceral tumor or melanoma. Embodiment 540. In any one of Embodiments 267 to 539, wherein the solid tumor is head and neck squamous cell carcinoma (HNSCC). Embodiment 541. In any one of Embodiments 267 to 539, wherein the solid tumor is a visceral tumor. Embodiment 542. In any one of Embodiments 267 to 539, wherein the solid tumor is melanoma. Pharmaceutical compositions Pharmaceutical compositions comprising a compound of Formula (I) used, either alone or in combination with an anti-PD-1 antibody, for the treatment of solid tumors are described below. Such pharmaceutical compositions can be used in any one of the enumerated embodiments provided herein, such as any one of Embodiments 131 to 266 or any one of Embodiments 400 to 542. Pharmaceutical compositions of the present invention comprise a therapeutically effective amount of 3-(5-amino-2-(4-(2-(3,3-difluoro-3-phosphonopropoxy)ethoxy)-2- methylphenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid (compound of Formula (I)), a suspension of aluminum hydroxide particles, a buffering agent, and one or more pharmaceutically acceptable excipients. In general the aluminum hydroxide particles are present as a 0.1-5% suspension, but preferably as a 0.1-2% suspension. The size distribution of the aluminum hydroxide particles is generally 1-20 micrometers, but preferably, the size distribution of the aluminum hydroxide particles is 2-10 micrometers. In a certain embodiment the aluminum hydroxide particles are present as a 0.3-0.4% suspension with a size distribution of 2-10 micrometers. Another embodiment is a 0.4% suspension of aluminum hydroxide particles with a size distribution of 2-10 micrometers. The pharmaceutically acceptable excipients that may be included in pharmaceutical compositions comprising the compound of Formula (I), include, but are not limited to, bulking agents, lyoprotectants, buffering agents, tonicity modifier, isotonic agents, antioxidants, antimicrobial agents, antibacterial agents, antifungal agents, solubilizing agents, surfactants and wetting agents. Such excipients for use in an injectable formulation are known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990 and Pharma Times, Vol.45, No.3, 2013 pp.65-77). The pharmaceutical composition also comprises water as the pharmaceutically and physiologically acceptable injectable fluid vehicle. In general bulking agents are included in a lyophilized product to provide bulk and structure to the lyophilzed powder; aiding in dissolution of the active agent. Lyoprotectants help to stabilize and prevent the degradation of the active agent during freeze-drying and storage. The bulking agents and lyoprotectants which may be included in pharmaceutical compositions comprising the compound of Formula (I) include, but are not limited to, sucrose, lactose, trehalose, mannitol, sorbitol, raffinose, glycine, histidine, polyethylene glycol and low molecular weight polyvinyl pyrrrollidones (i.e. Povidone K12 and Povidone K17). Buffering agents are included into pharmaceutical compositions to adjust and stabilize pH and optimize active agent solubility and stability. Buffering agents are also used in pharmaceutical compositions comprising the compound of Formula (I) to ensure that the phosponic acid groups of the compound of Formula (I) are ionized (e.g. in the pH range of 7-9). The buffering agents which may be included in pharmaceutical compositions comprising the compound of Formula (I) include, but are not limited to, Tris, glycine, meglumine, histidine and citrate/citric acid. Tonicity modifiers and isotonic agents are included into pharmaceutical compositions to ensure the formulation is isotonic with human plasma. The tonicity modifiers and isotonic agents which may be included in pharmaceutical compositions comprising the compound of Formula (I), include, but are not limited to, dextrose, glycerol, sodium chloride, glycerin and mannitol. Antioxidants are used to prevent/minimize the oxidation of active agent or excipients during storage, whereas antimicrobial agents are used to prevent the growth of micro-organisms. The antioxidants which may be included in pharmaceutical compositions comprising the compound of Formula (I) include, but are not limited to, ascorbic acid, acetylcysteine, sulfurous acid salts (bisulfite, metabisulfite), monothioglyercol, butylated hydroxy toluene (BHT), butylated hydroxyanisole (BHA) and thiourea. The antimicrobial agents which may be included in pharmaceutical compositions comprising the compound of Formula (I) include, but are not limited to, phenol, meta-cresol, benzyl alcohol, parabens methyl, propyl, butyl), benzalkonium chloride, chlorobutanol, thimerosal, and phenylmercuric salts (acetate, borate, nitrate). Solubilizing agents, which can be broadly classified into surfactants and co-solvents, help in dissolving or increasing the active agent solubility into the formulation. The surfactants which may be included in pharmaceutical compositions comprising the compound of Formula (I) include, but are not limited to, polyoxyethylene sorbitan monooleate (Tween 80), sorbitan monooleate polyoxyethylene sorbitan monolaurate (Tween 20), lecithin, polyoxyethylene– polyoxypropylene copolymers (Pluronics). Surfactants may also act as wetting agents and the surfactant/wetting agents which may be included in pharmaceutical compositions comprising the compound of Formula (I) include, but are not limited to, lecithin, Polysorbate 20, Polysorbate 80, Pluronic F-68 and Sorbitan trioleate (span 85). Pharmaceutical compositions comprising the compound of Formula (I) can be prepared using processes which include admixing the compound of Formula (I) with one or more pharmaceutically acceptable excipients and water. Alternatively, pharmaceutical compositions comprising the compound of Formula (I) can be prepared by admixing a reconstituted lyophilisate (reconstituted with water) with a solution comprising aluminum hydroxide particles, wherein the lyophilisate comprises the compound of Formula (I), a buffering agent (pH 7.0 to 8.0), a bulking agent and a lyoprotectant. In addition, pharmaceutical compositions comprising the compound of Formula (I) can be prepared by admixing a reconstituted lyophilisate (reconstituted with water) with a solution comprising aluminum hydroxide particles, wherein the lyophilisate comprises the compound of Formula (I), a buffering agent (pH 7.0 to 8.0), a bulking agent, a lyoprotectant, a surfactant and a wetting agent. Certain aspects and examples of pharmaceutical compositions comprising the compound of Formula (I) used in any one of Embodiments 131 to 266 or any one of Embodiments 400 to 542 are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the pharmaceutical composition comprising the compound of formula (I) used to treat solid tumors. Embodiment 543. A pharmaceutical composition comprising a compound of Formula (I), a suspension of aluminum hydroxide particles, and one or more pharmaceutically acceptable excipients. Embodiment 544. A pharmaceutical composition comprising a compound of Formula (I), a suspension of aluminum hydroxide particles, and a buffering agent. Embodiment 545. A pharmaceutical composition comprising a compound of Formula (I), a suspension of aluminum hydroxide particles, a buffering agent, and one or more pharmaceutically acceptable excipients. Embodiment 546. A pharmaceutical composition comprising a compound of Formula (I), a suspension of aluminum hydroxide particles, and a buffering agent, wherein the composition has a pH in the range of 6.5 to 9.0. Embodiment 547. A pharmaceutical composition comprising a compound of Formula (I), a suspension of aluminum hydroxide particles, a buffering agent, and one or more pharmaceutically acceptable excipients, wherein the composition has a pH in the range of 6.5 to 9.0. Embodiment 548. A pharmaceutical composition comprising a compound of Formula (I), a suspension of aluminum hydroxide particles, and a buffering agent, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 549. A pharmaceutical composition comprising a compound of Formula (I), a suspension of aluminum hydroxide particles, a buffering agent, and one or more pharmaceutically acceptable excipients, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 550. A pharmaceutical composition comprising a compound of Formula (I), a suspension of aluminum hydroxide particles, a buffering agent, and sucrose, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 551. A pharmaceutical composition comprising a compound of Formula (I), a suspension of aluminum hydroxide particles, a buffering agent, and mannitol, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 552. A pharmaceutical composition comprising a compound of Formula (I), a suspension of aluminum hydroxide particles, and Tris buffer, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 553. A pharmaceutical composition comprising a compound of Formula (I), a suspension of aluminum hydroxide particles, Tris buffer, and sucrose, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 554. A pharmaceutical composition comprising 0.5 to 2 mg/mL of a compound of Formula (I), 5-100 mM Tris buffer, 5-10% (w/v) sucrose, and a suspension of aluminum hydroxide particles having an aluminum content of 1 to 4 mg/mL, wherein the composition has a pH in the range of 7.0 to 8.0 Embodiment 555. A pharmaceutical composition comprising 0.5 to 2 mg/mL of a compound of Formula (I), 5-50 mM Tris buffer, 5-10% (w/v) sucrose, and a suspension of aluminum hydroxide particles having an aluminum content of 1 to 4 mg/mL, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 556. A pharmaceutical composition comprising 0.5 to 2 mg/mL of a compound of Formula (I), 5-20 mM Tris buffer, 5-10% (w/v) sucrose, and a suspension of aluminum hydroxide particles having an aluminum content of 1 to 4 mg/mL, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 557. A pharmaceutical composition comprising 1 mg/mL of a compound of Formula (I), 5-20 mM Tris buffer, 5-10% (w/v) sucrose, and a suspension of aluminum hydroxide particles having an aluminum content of 2 mg/mL, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 558. A pharmaceutical composition comprising 1 mg/mL of a compound of Formula (I), 16 mM Tris buffer, 7.5% (w/v) sucrose, and a suspension of aluminum hydroxide particles having an aluminum content of 2 mg/mL, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 559. A pharmaceutical composition comprising 1 mg/mL of a compound of Formula (I), 5 mM Tris buffer, 8.25% (w/v) sucrose, and a suspension of aluminum hydroxide particles having an aluminum content of 2 mg/mL, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 560. A pharmaceutical composition comprising 1 mg/mL of a compound of Formula (I), 16 mM Tris buffer, 7.5% (w/v) sucrose, and a suspension of aluminum hydroxide particles having an aluminum content of 2 mg/mL, wherein the composition has a pH of 7.5 +/- 0.5. Embodiment 561. A pharmaceutical composition comprising 1 mg/mL of a compound of Formula (I), 5 mM Tris buffer, 8.25% (w/v) sucrose, and a suspension of aluminum hydroxide particles having an aluminum content of 2 mg/mL, wherein the composition has a pH of 7.5 +/- 0.5. Embodiment 562. A pharmaceutical composition comprising 1 mg/mL of a compound of Formula (I), 16 mM Tris buffer, 7.5% (w/v) sucrose, and a suspension of aluminum hydroxide particles having an aluminum content of 2 mg/mL, wherein the composition has a pH of 7.5 +/- 0.3. Embodiment 563. A pharmaceutical composition comprising 1 mg/mL of a compound of Formula (I), 5 mM Tris buffer, 8.25% (w/v) sucrose, and a suspension of aluminum hydroxide particles having an aluminum content of 2 mg/mL, wherein the composition has a pH of 7.5 +/- 0.3. Embodiment 564. A pharmaceutical composition comprising a compound of Formula (I), a suspension of aluminum hydroxide particles, Tris buffer, and mannitol, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 565. A pharmaceutical composition comprising 0.5 to 2 mg/mL of a compound of Formula (I), 5-100 mM Tris buffer, 5-10% (w/v) mannitol, and a suspension of aluminum hydroxide particles having an aluminum content of 1 to 4 mg/mL, wherein the composition has a pH in the range of 7.0 to 8.0 Embodiment 566. A pharmaceutical composition comprising 0.5 to 2 mg/mL of a compound of Formula (I), 5-50 mM Tris buffer, 5-10% (w/v) mannitol, and a suspension of aluminum hydroxide particles having an aluminum content of 1 to 4 mg/mL, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 567. A pharmaceutical composition comprising 0.5 to 2 mg/mL of a compound of Formula (I), 5-20 mM Tris buffer, 5-10% (w/v) mannitol, and a suspension of aluminum hydroxide particles having an aluminum content of 1 to 4 mg/mL, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 568. A pharmaceutical composition comprising 1 mg/mL of a compound of Formula (I), 5-20 mM Tris buffer, 5-10% (w/v) mannitol, and a suspension of aluminum hydroxide particles having an aluminum content of 2 mg/mL, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 569. A pharmaceutical composition comprising 1 mg/mL of a compound of Formula (I), 16 mM Tris buffer, 7.5% (w/v) mannitol, and a suspension of aluminum hydroxide particles having an aluminum content of 2 mg/mL, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 570. A pharmaceutical composition comprising 1 mg/mL of a compound of Formula (I), 5 mM Tris buffer, 8.25% (w/v) mannitol, and a suspension of aluminum hydroxide particles having an aluminum content of 2 mg/mL, wherein the composition has a pH in the range of 7.0 to 8.0. Embodiment 571. A pharmaceutical composition comprising 1 mg/mL of a compound of Formula (I), 16 mM Tris buffer, 7.5% (w/v) mannitol, and a suspension of aluminum hydroxide particles having an aluminum content of 2 mg/mL, wherein the composition has a pH of 7.5 +/- 0.5. Embodiment 572. A pharmaceutical composition comprising 1 mg/mL of a compound of Formula (I), 5 mM Tris buffer, 8.25% (w/v) mannitol, and a suspension of aluminum hydroxide particles having an aluminum content of 2 mg/mL, wherein the composition has a pH of 7.5 +/- 0.5. Embodiment 573. A pharmaceutical composition comprising 1 mg/mL of a compound of Formula (I), 16 mM Tris buffer, 7.5% (w/v) mannitol, and a suspension of aluminum hydroxide particles having an aluminum content of 2 mg/mL, wherein the composition has a pH of 7.5 +/- 0.3. Embodiment 574. A pharmaceutical composition comprising 1 mg/mL of a compound of Formula (I), 5 mM Tris buffer, 8.25% (w/v) mannitol, and a suspension of aluminum hydroxide particles having an aluminum content of 2 mg/mL, wherein the composition has a pH of 7.5 +/- 0.3. Embodiment 575. The pharmaceutical composition of any one of Embodiments 426 to 457, wherein the compound of Formula (I) is present in a therapeutically effective amount. Embodiment 576. The pharmaceutical composition of any one of Embodiments 426 to 458, wherein the composition further compises polyethylene glycol, polyoxyethylene sorbitan monooleate (Tween 80) or Pluronic F-68. Embodiment 577. The pharmaceutical composition of any one of Embodiments 426 to 459, wherein the composition further compises 1-2% of polyethylene glycol, polyoxyethylene sorbitan monooleate (Tween 80) or Pluronic F-68. EXAMPLES A Phase I/Ib study of intratumorally administered LHC165 (Compound of Formula (I) as a single agent and in combination with PDR001 for the treatment of advanced malignancies A phase I/Ib, open label, multicenter, dose-escalation and dose-expansion study of the safety and tolerability of intratumorally administered LHC165 single agent and in combination with PDR001 was performed in patients with advanced malignancies. A Bayesian logistic regression model, with overdose control, was used to guide the dose escalation and to estimate the maximum tolerated dose (MTD)/recommended dose for expansion (RDE). Safety assessments used included (a) using Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1, (b) incidence and severity of safety of adverse events (AEs) and serious adverse events (SAEs), including changes in laboratory values, vital signs, and electrocardiograms (ECGs), and (c) dose interruptions, reductions and dose intensity. Overall response rate was defined as per Response Evaluation Criteria in Solid Tumors (RECIST 1.1, iRECIST). As of the data cut-off date of May 11, 2020, 36 patients received LHC165, 17 as a single agent and 19 in combination with PDR001. The dose escalation part of the study evaluated doses of 100 µg, 200 µg, 400 µg, and 600 µg of LHC165 once every two weeks (bi-weekly) as a single agent (SA) and in combination with PDR001 at a dose of 400 mg once every four weeks (Q4W). There were no dose limiting toxicities observed in the patients receiving LHC165 alone. One DLT of G3 pancreatitis was observed in 1 patient treated with LHC165 in combination with PDR001. The most common AEs (all grades) suspected to be related to study treatment were pyrexia (16.7%), injection site reaction (13.9%), chills (8.3%), and pruritus (8.3%). Pharmacokinetic (PK) studies demonstrated rapid release of LHC165 with Tmax of ~1 hr post dose and moderate elimination with consistent terminal T½ across different doses (~ 23 hrs). PK exposure increased with dose in the range of 100 µg to 600 µg. No accumulation was observed in the biweekly dosing interval. No drug-drug interaction was observed between LHC165 and PDR001. In 34 evaluable patients, 3 had confirmed partial responses (PR) per RECIST v 1.1 (LHC165200 µg SA, LHC165600 µg SA, and LHC165400 µg + PDR001) and 4 patients had stable disease as best overall response. The dose escalation part of the study has been completed. RDE has not yet been declared.

Claims

CLAIMS: 1. A method for treating a solid tumor in a subject in need thereof, comprising intratumorally administering a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg,

and intravenously administering an anti-PD-1 antibody either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab.

2. The method for treating a solid tumor of claim 1, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 400 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg.

3. The method for treating a solid tumor of claim 1 or claim 2, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg.

4. The method for treating a solid tumor of any one of claims 1 to 3, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 400 µg, and the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg.

5. The method for treating a solid tumor of claim 1 or claim 2, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg.

6. The method for treating a solid tumor of any one of claims 1, 2 or 5, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 600 µg, and the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg.

7. The method for treating a solid tumor of any one of claims 1 to 6, wherein the compound of Formula (I) is intratumorally administered for one or more cycle periods and the anti-PD-1 antibody is intravenously administered for one or more cycle periods.

8. A therapeutic regimen for treating a solid tumor, comprising intratumorally administering a compound of Formula (I) once a week, once every two weeks, once every three weeks or once every four weeks at a flat dose of about 100 µg to about 600 µg

9. The therapeutic regimen for treating a solid tumor of claim 8, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 400 µg to about 600 µg and the anti-PD-1 antibody is intravenously administered once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg.

10. The therapeutic regimen for treating a solid tumor of claim 8 or claim 9, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 400 µg and the anti-PD-1 antibody is intravenously administered once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg.

11. The therapeutic regimen for treating a solid tumor of any one of claims 8 to 10, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 400 µg and administering the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg.

12. The therapeutic regimen for treating a solid tumor of claim 8 or claim 9, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 600 µg and the anti-PD-1 antibody is intravenously administered once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg.

13. The therapeutic regimen for treating a solid tumor of any one of claims 8, 9 or 12, wherein the compound of Formula (I) is intratumorally administered once every two weeks at a flat dose of about 600 µg and the anti-PD-1 antibody is intravenously administered once every four weeks at a flat dose of about 400 mg.

14. The therapeutic regimen for treating a solid tumor of any one of claims 8 to 13, wherein the compound of Formula (I) is intratumorally administered for one or more cycle periods and the anti-PD-1 antibody is intravenously administered for one or more cycle periods.

15. The method for treating a solid tumor of any one of claims 1 to 7, or the therapeutic regimen for treating a solid tumor of any one of claims 8 to 14, further comprising one or more dose delays for the compound of Formula (I), wherein each dose delay is for one or more cycle periods.

16. The method for treating a solid tumor of any one of claims 1 to 7, or the therapeutic regimen for treating a solid tumor of any one of claims 8 to 14, further comprising one or more dose delays for the compound of Formula (I), wherein each dose delay is for two or more consecutive cycle periods.

17. The method for treating a solid tumor of any one of claims 1 to 7, or the therapeutic regimen for treating a solid tumor of any one of claims 8 to 14, further comprising one or more dose delays for the compound of Formula (I), wherein each dose delay is for two consecutive cycle periods.

18. The method for treating a solid tumor of any one of claims 1 to 7, or the therapeutic regimen for treating a solid tumor of any one of claims 8 to 14, further comprising a dose delay for the compound of Formula (I), wherein the dose delay is for two consecutive cycle periods and the compound of Formula (I) is intratumorally administered for two consecutive cycle periods before the dose delay.

19. The method for treating a solid tumor of any one of claims 1 to 7, or the therapeutic regimen for treating a solid tumor of any one of claims 8 to 14, further comprising a dose delay for the compound of Formula (I), wherein the dose delay is for two consecutive cycle periods, and wherein the compound of Formula (I) is intratumorally administered for two consecutive cycle periods before the dose delay, and the compound of Formula (I) is intratumorally administered for two consecutive cycle periods after the dose delay.

20. The method for treating a solid tumor of any one of claims 7 or to 15 to 19, or the therapeutic regimen for treating a solid tumor of any one of claims 14 to 19, wherein each cycle period is 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days.

21. The method for treating a solid tumor of any one of claims 7 or to 15 to 20, or the therapeutic regimen for treating a solid tumor of any one of claims 14 to 20, wherein each cycle period is 28 days.

22. A therapeutic regimen for treating a solid tumor, wherein the therapeutic regimen has a six cycle period dosing schedule comprising: c) intratumorally administering a compound of Formula (I)

for two consecutive cycle periods (Cycles 1 and 2), followed by a dose delay for two consecutive cycle periods (Cycles 3 and 4), and then followed by additional intratumoral administration of the compound of Formula (I) for two consecutive cycle periods (Cycles 5 and 6); and d) intravenously administering an anti-PD-1 antibody for each of the six cycle periods; and wherein: each cycle period is 28 days; the compound of Formula (I) is intratumorally administered at a flat dose of about 100 µg to about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6, and the anti-PD-1 antibody is spartalizumab which is intravenously administered at a flat dose of 400 mg on Day 1 of Cycles 1, 2, 3, 4, 5 and 6.

23. The therapeutic regimen for treating a solid tumor of claim 22, wherein the compound of Formula (I) is intratumorally administered at a flat dose of about 400 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6.

24. The therapeutic regimen for treating a solid tumor of claim 22, wherein the compound of Formula (I) is intratumorally administered at a flat dose of about 600 µg on Day 1 and Day 15 of Cycles 1, 2, 5 and 6.

25. The therapeutic regimen of any one of claims 22 to 24, wherein the therapeutic regimen further comprises intravenously administering the anti-PD-1 antibody for one or more additional cycle periods after Cycle 6.

26. Use of a of a compound of Formula (I) in combination with an anti-PD-1 antibody for the treatment of a solid tumor, wherein the compound of Formula (I) is administered intratumorally once every two weeks at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is intravenously administered either once every three weeks at a flat dose of about 300 mg or once every four weeks at a flat dose of about 400 mg, wherein the anti-PD-1 antibody is spartalizumab.

27. A combination comprising a compound of Formula (I) and an anti-PD-1 antibody for the use in the treatment of a solid tumor, wherein the compound of Formula (I) is at a flat dose of about 100 µg to about 600 µg, and the anti-PD-1 antibody is at a flat dose of about 300 mg or about 400 mg, and wherein the anti-PD-1 antibody is spartalizumab.

28. The method of any one of claims 1 to 7 or 15 to 21, the therapeutic regimen of any one of claims 8 to 14 or 15 to 25, the use of claim 26 or the combination of claim 27, wherein the anti-PD-1 antibody comprises: (a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 5, a VHCDR2 amino acid sequence of SEQ ID NO: 6, and a VHCDR3 amino acid sequence of SEQ ID NO: 4; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 14, a VLCDR2 amino acid sequence of SEQ ID NO: 15, and a VLCDR3 amino acid sequence of SEQ ID NO: 16; (b) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 2; a VHCDR2 amino acid sequence of SEQ ID NO: 3; and a VHCDR3 amino acid sequence of SEQ ID NO: 4; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 11, a VLCDR2 amino acid sequence of SEQ ID NO: 12, and a VLCDR3 amino acid sequence of SEQ ID NO: 13; (c) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1; a VHCDR2 amino acid sequence of SEQ ID NO: 6; and a VHCDR3 amino acid sequence of SEQ ID NO: 4; and a a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 14; a VLCDR2 amino acid sequence of SEQ ID NO: 15; and a VLCDR3 amino acid sequence of SEQ ID NO: 16; or (d) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1; a VHCDR2 amino acid sequence of SEQ ID NO: 3; and a VHCDR3 amino acid sequence of SEQ ID NO: 4; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 11; a VLCDR2 amino acid sequence of SEQ ID NO: 12; and a VLCDR3 amino acid sequence of SEQ ID NO: 13.

29. The method of any one of claims 1 to 7 or 15 to 21, the therapeutic regimen of any one of claims 8 to 25, the use of claim 26, or the combination of claim 27, wherein the anti- PD-1 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 21.

30. The method of any one of claims 1 to 7 or 15 to 21, the therapeutic regimen of any one of claims 8 to 14 or 15 to 25, the use of claim 26 or the combination of claim 27, wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 23.

31. The method of any one of claims 1 to 7, 15 to 21 or 28 to 30, the therapeutic regimen of any one of claims 8 to 25 or 28 to 30, the use of claim 26 or 28 to 30, or the combination of claim 27 or 28 to 30, wherein the solid tumor is a breast cancer tumor, a bladder cancer tumor, a head and neck cancer tumor, head and neck squamous cell carcinoma (HNSCC), a non-small cell lung cancer tumor, a small cell lung cancer tumor, a colorectal cancer tumor, a gastrointestinal stromal tumor, a gastroesophageal carcinoma, a renal cell cancer tumor, a prostate cancer tumor, a liver cancer tumor, a colon cancer tumor, a pancreatic cancer tumor, an ovarian cancer tumor, a lymphoma, a cutaneous T-cell lymphoma, a visceral tumor or melanoma.

32. The method of any one of claims 1 to 7, 15 to 21 or 28 to 31, the therapeutic regimen of any one of claims 8 to 25 or 28 to 31, the use of claim 26 or 28 to 31, or the combination of claim 27 or 28 to 31, the use of any one of claims 36 to 40 or 46 to 50, or the combination of any one of claims 41 to 45 or 46 to 50, wherein the solid tumor is a breast cancer tumor, head and neck squamous cell carcinoma (HNSCC), a visceral tumor or melanoma.

33. The method of any one of claims 1 to 7, 15 to 21 or 28 to 30, the therapeutic regimen of any one of claims 8 to 25 or 28 to 30, the use of claim 26 or 28 to 30, or the combination of claim 27 or 28 to 30, the use of any one of claims 36 to 40 or 46 to 50, or the combination of any one of claims 41 to 45 or 46 to 50, wherein the solid tumor is head and neck squamous cell carcinoma (HNSCC), a visceral tumor or melanoma.